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Abstract 
Peptide YY (PYY) is a gut hormone belonging to the pancreatic polypeptide (PP) family, 
and is released by the L-cells of the gastrointestinal tract following food intake. There 
are two main endogenous forms: PYY1-36 and PYY3-36, with the latter having a high 
selectivity for the Y2-receptor which is associated with reduced food intake. The use of 
PYY3-36 as an anti-obesity and type II diabetes drug is therefore of great interest. 
Peptide hormones have short circulating half-lives; therefore it is of high importance to 
develop a strategy to overcome this for the development of peptide drugs. The use of 
lipidation is a promising method as it allows the peptide to bind to serum albumin, 
increasing molecular weight and thus reducing renal filtration.  
In this thesis the impact of lipidation, and the position of lipidation on the self-assembly 
of PYY3-36 and various truncated derivatives are investigated. A wide range of physical 
characterisation techniques are employed to understand self-assembly and 
aggregation. Some cytotocompatibility studies using MTT assays on human colorectal 
cancer cells are also carried out in order to understand cytotoxicity. 
It was apparent throughout the project that lipidation significantly impacted the self-
assembly, by helping to drive aggregation as a result of the increased amphiphilicity 
caused by the addition of the lipid chain, which in this case was a palmitoyl chain. The 
full PYY3-36 peptide and the lipidated derivatives had predominantly α-helical secondary 
structures. They differed largely when they aggregated however, with the native peptide 
being mostly monomers with some nanotapes, and the lipidated peptides having micelle 
and fibril conformations depending on pH. In addition to this the lipidated peptides 
formed gels under specific conditions whereas the native peptide did not.  
Investigations into the truncated peptide fragments further enhanced the impact of 
lipidation, where the lipidated fragments had micelle and fibril conformation, whereas 
the native fragments did not aggregate at all. Cytocompatibility studies found the 
lipidated peptides to be cytotoxic at concentrations above the cmc, suggesting that 
aggregation causes the peptides to become cytotoxic.  
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Chapter 1 – Introduction 
1.1 Peptides 
Peptides are small assemblies of amino acid monomers linked by covalent peptide 
bonds. There are 20 natural amino acids which make up the building blocks for various 
peptides and proteins. Most amino acids with the exception of proline consist of an 
alpha carbon atom to which a hydrogen atom, an amino group, a carboxyl group, and a 
side chain R group are attached.1 The only variable group on an amino acid is the R 
group, and it is this that is responsible for the different properties of the various amino 
acids.  
The peptide bond is formed by the linking of two amino acids, with the elimination of 
water via a condensation reaction between the neighbouring –NH2 and –COOH groups, 
resulting in a dipeptide (figure 1.1).1  
 
 
 
 
 
The peptide bond has a double bond character due to delocalisation of the lone pair of 
electrons on the nitrogen atom, which means that no rotation is possible around the 
bond. This allows the peptide to have either a cis or trans conformation. The 
Figure 1.1. Structure of a peptide bond. 
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delocalisation of electrons results in the peptide bond having resonance, meaning it is 
relatively unreactive under physiological conditions which is important in biological 
systems (figure 1.2).2 
 
 
 
Multiple amino acid residues bound by peptide bonds are known as polypeptides, and 
these are what make up the backbone structures of proteins. Proteins are classified as 
having around 50 or more amino acid monomers in the polypeptide chain. There are 20 
different types of amino acid that can be combined to form a protein, and it is the 
sequence of amino acids that determines the structure and function of a protein.  
There are four categories of peptide structure; primary, secondary, tertiary and 
quaternary. The primary structure of a peptide refers to the amino acid sequence from 
the N-terminus to the C-terminus. The secondary structure is when the peptide is held 
into a structure, such as an alpha helix or a beta sheet. The secondary structures are 
held together by hydrogen bonds. Tertiary structure is the final three dimensional 
shape, and it is held together by interactions between the R groups. These interactions 
can be ionic, hydrogen bonding, van der Waals forces and also sulphur bridges. 
 
Figure 1.2. Resonance structures of a peptide bond. 
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1.1.2 Peptide self-assembly 
 
Supramolecular self-assembly is the ability of molecules to spontaneously form ordered 
nanostructures via non-covalent interactions such as van der Waals, electrostatic, 
hydrogen bonding, and stacking interactions.3 Self-assembly is important in many 
biological systems such as the self-assembly of lipid membranes, the DNA double helix, 
and folded proteins.3-4 Peptides can self-assemble into a wide range of different 
nanostructures depending on the hydrophile/lipophile balance of molecules, the 
number and sequence of amino acids, as well as the interactions between the peptide 
units.5 Hydrogen bonding between backbones of peptides plays an important role in 
self-assembly and can cause the peptide monomers to pack longitudinally into β-sheets, 
a common secondary structure arising from peptide self-assembly, and they either have 
anti-parallel or parallel conformations (Figure 1.3). Peptides with a β-sheet secondary 
structure often form fibril structures that can subsequently cross-link to form hydrogels, 
allowing them to act as slow releasing systems in drug delivery.6 On the other hand they 
can also be detrimental by forming amyloid fibrils, heavily associated with 
neurodegenerative diseases, such as Alzheimer’s disease. Another common secondary 
structure formed by self-assembly is the α-helix (Figure 1.4), characterised by a single 
spiral chain of amino acids stabilised by hydrogen bonding between N-H and C=0 groups. 
An example of an α-helical compound is the iron and oxygen binding protein, myoglobin, 
found in most mammals.7 Peptides that typically form α-helices exhibit amino acids of 
similar properties every 3-4 residues, giving rise to the structural repeat of 3.6 residues 
per α-helical turn. 
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As a result of self-assembly being so important in nature, the use of self-assembling 
peptides for use in therapeutics has gained increasing attention. This is due to them 
being versatile molecules with tuneable functionality, and high biocompatibility and 
biodegradability.3 A polypeptide for example can consist of a targeting sequence, a self-
assembly domain, and a biologically active peptide.8 This is extremely attractive from an 
industrial point of view as it prevents the need for complex synthetic chemical reactions. 
Consequently, peptides provide a unique platform for the design of nanomaterials with 
controllable structural features. 
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Figure 1.3. Parallel and anti-parallel β-sheet orientations. 
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Environmental factors such as pH and temperature play a key role in peptide self-
assembly. A simple change of environment allows for fine tuning of peptide self-
assembly for a variety of applications. A study by Stevens et al discovered that is was 
possible to control the assembly of coiled-coil based gold nanoparticles using a leucine 
zipper-like peptide, with changes in pH and temperature. It was found that the 
nanoparticles aggregated when the pH was lowered to 4.5, and disassembly occurred as 
the temperature was increased due to thermal unfolding of the α-helices.9  In another 
study by Thanh et al. the aggregation of an endogenous opioid peptide neurotransmitter 
derivative, with the sequence YVIFL, as a function of pH was investigated. Aggregates 
were obtained throughout the pH range 2-11, but with different morphologies ranging 
from amorphous structures at low pH to fibrils at increased pH.10 The prevailing driving 
forces behind aggregation are salt bridges, hydrogen-bonds, hydrophobicity, and net 
Figure 1.4. Illustration of an α-helix showing hydrogen bonding between C=O and 
N-H groups (dashed lines). Each helical turn contains 3.6 amino acid residues. 
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charge contributions from ionizable side chains, with charged residues causing 
interruptions in contiguous stretches of hydrophobic sequences, as well as causing 
electrostatic repulsion between units.10 With this is mind, the propensity of the YVIFL 
peptide to aggregate into amorphous structures at low pH is more clearly understood. 
1.2 Peptide amphiphiles  
 
Most self-assembling molecules are amphiphilic, meaning they have both hydrophobic 
and hydrophilic character. Peptide amphiphiles are a class of molecules comprised of 
either hydrophobic and hydrophilic peptide sequences, or a hydrophilic peptide with an 
attached hydrophobic group, which is usually an alkyl chain. The structure of a peptide 
amphiphiles has four key domains (Figure 1.5). Firstly there is a hydrophobic section, 
typically an alkyl chain. Secondly there is the peptide sequence which forms 
intermolecular hydrogen bonding. Thirdly there is a section of charged amino acid 
residues to enhance the solubility of the peptide in water. The final structural feature 
allows the peptide to interact with biomolecules, cells, or proteins, and this is often 
through epitopes (part of antigens recognised by the immune system).6  
 
 
 
 
Figure 1.5. Structure of a peptide amphiphile showing the four different domains: a 
hydrophobic domain, a β-sheet section, a charged group, and a bioactive head group.6 
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As with other amphiphilic molecules, above a critical aggregation concentration peptide 
amphiphiles associate through non-covalent interactions to form ordered assemblies of 
different sizes, from nanometres to microns.11 Molecules that contain both polar and 
non-polar elements minimise unfavourable interactions with the aqueous environment 
via aggregation, which allows the hydrophilic moieties to be exposed to the aqueous 
environment, and the hydrophobic moieties to be protected. When aggregation occurs, 
a variety of assemblies can be formed depending on many parameters such as 
concentration, pH, temperature and geometry. The assemblies formed range from 
micelles to bilayer structures, such as vesicles, as well as fibrils and gels as mentioned 
already (Figure 1.3).12  
Micelles consist of a hydrophobic inner core surrounded by a hydrophilic outer shell that 
is exposed to a solvent, and their structures can be spheres, disks or wormlike 
assemblies.13 Micelles form spontaneously when the concentration is above a critical 
micelle concentration and temperature.14 Amphiphiles with an intermediate level of 
hydrophobicity prefer to assemble into bilayer vesicles. Vesicles are spherical, hollow, 
lamellar structures that surround an aqueous core. The hydrophobic moiety faces 
inwards and forms the inner section of the bilayer, and the hydrophilic moiety is exposed 
to the aqueous environment on the inner and outer surface. Micelle structures have a 
hydrophobic interior and hydrophilic exterior.15 
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Figure 1.6. Scheme to show the possible self-assembled structures of typical peptide 
amphiphiles. Each amino acid is 3.5 Å long, meaning that a peptide containing 10 
amino acids will be 3.5 nm approximately.16 
 
There is normally a distinct relationship between the amphiphilic character of a peptide 
and its function in that the amphiphilic character determines the self-assembly 
properties, and in turn this is what gives the peptide its functionality. The level of 
amphiphilicity can vary significantly in peptides and proteins; as such they can display 
regions that are either hydrophobic or hydrophilic in nature. An example of this is the 
cylindrical structure of an α-helix, as it could contain a section of hydrophobic residues 
along one face of the cylinder and a hydrophilic section of residues on the opposite face 
of the cylinder. For β-sheet structures, the peptide chain can be composed of alternating 
hydrophilic and hydrophobic residues, so that the side chains of the residues are 
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displayed on opposite faces of the sheet (figure 1.3).17  In the cell membrane peptides 
fold into helices and sheets to allow the non-polar residues to interact with the 
membrane interior, and to allow the polar residues to be exposed to the aqueous 
environment. This self-assembly allows the peptides to further optimise their 
interaction with the surroundings. 
Peptide amphiphiles are very useful in biomedical applications, and can be utilised to 
act as therapeutic agents to treat diseases by transporting drugs across membranes to 
specific sites. They can then be metabolised into lipids and amino acids, which are then 
easily removed in the kidneys.18 This occurs by the hydrophobic tail being able to cross 
the cell membrane, allowing the peptide epitope to target a specific cell by a ligand-
receptor complex.19 Other applications of peptide amphiphiles are use in antimicrobials, 
skincare and cosmetics, and also gene delivery to name a few.20  
1.3 Lipidated Peptides 
 
Lipidated peptides are a type of peptide amphiphile that incorporate one or more 
alkyl/lipid chains, attached to a peptide head group. As with peptide amphiphiles, they 
self-assemble depending on the hydrophilic/hydrophobic balance, as well interactions 
between the peptide units, which is dependent on the charge of the amino acid 
residues.21 Lipidated peptides combine the structural features of amphiphilic 
surfactants with the functions of bioactive peptides, and they are known to assemble 
into a variety of nanostructures, similar to those mentioned for peptide amphiphiles.6, 
12 
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Peptide lipidation occurs naturally and is a posttranslational modification carried out in 
order to maintain cellular functions, of which there are many different types. Examples 
include ghrelin (a peptide hormone associated with feeding), and bacterial antibiotics 
that aren’t synthesised in the ribosome.22 Further examples include those produced by 
the Bacillus subtilis family which are composed of a cyclic structure made up of 7-10 
amino acids, and a β-hydroxy fatty acid chain of varying length ranging from 13-19 
carbon atoms.23 These can be divided into three families depending on the structure of 
the cyclic peptide sequence: surfactins, iturins, and fengycins.24-26 Lipidated peptides 
produced by Bacillus strains have many useful bio-activities such as anti-bacterial, anti-
viral, anti-fungal, and anti-tumour properties,23-24  making them very attractive for use 
in a wide range of industries. As the name implies, surfactins are potent biosurfactants 
(surfactants produced by bacteria, yeast, or fungi), and they have been shown to reduce 
the surface tension of water from 72 to 27 mN/m at very low concentrations.27 
Furthermore, surfactins are also able to permeabilize lipid membranes, allowing them 
to have specific antimicrobial and antiviral activities.24, 28-29 Since surfactins are 
biosurfactants, they have diverse functional properties. These include low toxicity, 
biodegradability and a higher tolerance towards variation of temperature and pH,24 
making them very interesting for use in a wide range of applications.  Iturins are pore‐
forming lipopeptides with antifungal activity, and this is dependent on the interaction 
with the cytoplasmic membrane of the target cells.24-25, 30 Mycosubtilin is an iturin 
isoform that can interact with membranes via its sterol alcohol group, to target 
ergosterol (a compound found in fungi) to give it antifungal properties.23, 31 Finally, 
fengycins are another class of biosurfactant produced by Bacillus subtilis, with antifungal 
activity against filamentous fungi.26, 30, 32 There are two classes of Fengycins, Fengycin A 
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and Fengycin B, with the two only differing by one amino acid at position 6 in the peptide 
sequence, with the former having an alanine residue, and the latter having valine.33  
Daptomycin is another naturally occurring lipidated peptide, produced by the Gram 
positive bacterium Streptomyces roseoporous. The structure of Daptomycin consists of 
a decanoyl lipid chain attached to a partially cyclised peptide head group.21 It has very 
potent antimicrobial properties and is used as an antibiotic to treat life-threatening 
conditions caused by Gram positive bacteria including MRSA (methicillin-resistant 
Staphylococcus aureus) and vancomycin resistant Enterococci.21, 34-35 As with the Bacillus 
subtillis lipidated peptides, the permeation of the cell membrane is what gives it its 
properties, and the mechanism of action with daptomycin is thought to involve the 
insertion of the decanoyl chain into the bacterial membrane to cause disruption. This 
then causes a serious depolarization resulting in the inhibition of various synthesis 
processes including those of DNA, protein and RNA, leading to apoptosis.36-38 
Due to the desirable properties of peptides such as high receptor affinity and bioactivity, 
and low toxicity, their use in therapeutics has great potential; shown by a fast growing 
market with over 100 approved peptide-based drugs.39 The disadvantages are that they 
have low oral bioavailability and stability. Lipidation as a chemical modification tool in 
the development of therapeutic agents has proven to be useful in overcoming these 
issues, with four lipidized peptide drugs currently approved for use in humans, and 
various others in clinical trials.22 Two of the approved drugs are long-acting anti-diabetic 
GLP-1 analogues liraglutide (Victoza®), and insulin detemir (Levemir®). The other two 
are the antiobiotics daptomycin, that has been discussed, and polymyxin B. 
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Lipidated peptides also have applications in other areas, such as use in the cosmetic 
industry.21 A commercially available lipidated peptide, Matrixyl, is used in anti-wrinkle 
creams. Matrixyl is a pentapeptide and has the sequence KTTKS, with an attached 
palmitoyl lipid chain, that is able to stimulate collagen and fibronectin production in 
fibroblasts.40 Several studies have shown promising results of palmitoyl-KTTKS, and 
topical formulations have been found to significantly reduce fine lines and wrinkles, 
helping to delay the aging process in the skin.41 The Hamley group have also carried out 
investigations of C16KTTKS, and found it so self-assemble into nanotapes in the pH range 
3-7, in addition to stimulating human dermal and corneal fibroblasts in a concentration 
dependant manner, suggesting that stimulation occurs above the critical aggregation 
concentration.42 
1.4 Peptide modification to increase stability 
 
Many strategies have been employed to increase the stability of peptide drugs, because 
although they have so many desirable characteristics, they are short lived in the body as 
a result of rapid degradation and clearance. With half-lives of some peptides and 
proteins only being a few minutes, they are very ineffective in drug delivery.43 
Mechanisms involved in their clearance include peripheral blood mediated elimination 
by proteolysis, real and hepatic elimination, and also receptor-mediated endocytosis.44 
One of the main reasons for such rapid clearance is molecular weight. Molecules that 
have a low molecular weight (40-50 kDa) are rapidly cleared by renal filtration via the 
glomerular filtration barrier (GBM) into the urine. As a result of this, increasing the size 
of a peptide drug is a good starting point to improve half-life.45 
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Peptide modifications to extend half-life include PEGylation, glycosylation, cyclization, 
serum albumin binding, and lipidation. PEGylation is the attachment of polyethylene 
glycol (PEG) chains to the peptide via covalent bonds, helping to increase molecular 
weight, and limit enzymatic degradation as a result of steric hindrance caused by adding 
the PEG.46 PEGylation offers a number of benefits for pharmaceutical applications such 
as improved water solubility, high mobility in solution, as well as low toxicity and 
immunogenicity. This does however depend on the molecular weight of the attached 
PEG.43, 47 PEGylation as a method to improve half-life has been successfully 
demonstrated many times; in one example it was shown that site specific mono-
PEGylation of GLP-1 led to a 16-fold increase in plasma half life time in rats.48 On the 
other hand, covalently attaching PEG can often lead to loss of biological activity.49  
Another chemical modification is the attachment of glycosyl (carbohydrate) units to the 
peptide to help with peptide delivery to target sights. The introduction of carboydrates 
to peptides can alter the physiological properties, to improve bioavailability. Advantages 
of this technique include increased metabolic stability, and facilitated transport across 
cell membranes, although of the most favourable aspects is their ability to promote oral 
absorption.50 Peptides have a very low oral availability (less than 1-2%),3, 51-52 as a result 
of insufficient absorption and rapid degradation and clearance, thus making this method 
an attractive one. N- and O- glycosylation in which carbohydrates are attached to the 
peptide are naturally occurring, where N- glycosylation occurs through the amine group 
of an asparagine residue to form an amide bond. O- glycosylation occurs via  serine or 
threonine residues, where the oxygen atom on the side chain binds to the carbohydrate 
through an ether bond. There is also non-natural glycosylation, known as chemical 
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glycosylation, which involves the attachment of carbohydrate units to different amino 
acid residues at the N-terminus of the peptide's sequence. A further way of carrying out 
glycosylation is by using enzymes, known as chemo-enzymatic glycosylation. This 
method is used for complex chemical synthesis.53-54 Chemical and chemo-enzymatic 
methods can be used for the synthesis of glycopeptides and glycoproteins.50 
Cyclization can also be used as a method to decrease proteolytic degradation and 
prolong half-life, to make the peptide conformation more rigid to hinder enzymatic 
cleavage. This method can however lead to loss of biological function due to the reduced 
flexibility making the peptide inactive.55 For example, side chain to side chain cyclization 
between asparagine (position 8) and lysine (position 12), of a growth regulating factor 
(GRF) analogue was found to increase the half-life from 17 minutes to more than 2 
hours.43  
Another way to extend half-life do is to bind serum albumin to the peptide. Human 
serum albumin is the most abundant plasma protein with a molecular weight of 66.4 
kDa56, and it is involved in many essential bodily functions to maintain homeostasis. As 
a result, albumin binding would significantly increase the molecular weight of the 
peptide, restricting it from being filtered into the urine by the GBM. Serum albumin has 
an extraordinary long half-life of 2-4 weeks which is much longer than other plasma 
proteins,57 due to it binding to the neonatal Fc receptor (FcRn). Fc receptors are proteins 
found on the surface of certain cells that help to protect the functions of the immune 
system, by binding to the Fc region of antibodies, which attach to pathogens and destroy 
them.  This mechanism of the neonatal FcRn involves albumin binding to the FcRn in an 
acidic pH environment to divert it from degradation in the lysosomal compartment of 
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the cell, and redirecting it to the plasma membrane, where it is released back into the 
blood plasma due to neutral pH.58  
As mentioned above, lipidation is a further technique to use when improving peptide 
stability and half-life. Attaching a lipid chain to the peptide head group has been found 
to inhibit proteolytic attack due to the lipid chain non-covalently interacting with serum 
albumin to increase the molecular weight, thus reducing renal filtration. Studies on a 
lipidated analogue of insulin, detemir, revealed a prolonged action as a result of its 
affinity for human serum albumin.59 As well as this, lipidation has been shown to 
enhance the interaction of peptides with cell membranes, allowing them to be up taken 
into the cell more readily compared to the peptide lacking the lipid moiety.60-61 There 
are three types of lipidation, and they differ based on the bond formation methods 
between the lipid and the peptide: amidation, esterification (S- or O-) and S-bond (ether 
or disulphide) formation. Amidation and O-esterification form strong covalent bonds 
that are irreversible, whereas the other two methods are weak and reversible covalent 
bonds. The method used, as well as the alkyl/lipid chain, position of lipidation, and the 
spacer used, all have significant impacts on physiochemical properties and bioactivity.22 
The level of lipophilicity can be significantly modulated by lipidation, and since 
lipophilicity is detrimental for the absorption, distribution, metabolism, and excretion of 
drugs, it provides a way of fine tuning peptides for use in therapeutics.  
A study on lipidation and PEGylation on the GLP-1 peptide was carried out and the 
results showed that lipidation had no significant effect on peptide activity in vitro,62 
whereas PEGylation did, especially when the PEG is attached to internal amino acids of 
the peptide e.g. positions 20 and 21. The reduction in activity from PEGylation compared 
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to lipidation is due to the loss of receptor affinity, and it is suggested that this is because 
of its increased molecular weight which causes steric hindrance.63-64  
1.5 Hydrogels 
Hydrogels are three dimensional supramolecular assemblies formed by cross-linking of 
polymer networks, that are able to absorb large amounts of water.65 Peptides can form 
hydrogels by non-covalent interactions of self-assembled structures to establish well-
ordered scaffolds, and these can be very useful in biotechnological and medical 
applications, in particular for use as slow drug delivery systems. Lipidated peptides can 
also form hydrogels, since the increased hydrophobic interactions from the addition of 
the hydrophobic chain facilitates its self-assembling ability.66 Hydrogels can be classified 
as either chemical or physical gels, with the former having covalent cross-linking bonds, 
and the latter having non-covalent bonds, as in the case of peptide hydrogels.67 
Chemical hydrogels result in strong irreversible gels due to the covalent bonding, and 
they may also possess harmful properties which makes them unfavourable for medical 
applications. Physical hydrogels on the other hand have high biocompatibility, aren’t 
toxic, and are also easily reversible, by simply changing an external stimulus such as pH 
or temperature; thus they are favourable for use in medical applications. 
There are two suggested mechanisms behind physical hydrogel formation, the first one 
being the gelation of nanofibrous peptide assemblies, usually observed for oligopeptide 
precursors. The precursors self-assemble into fibers, tapes, tubes, or ribbons that 
entangle to form non-covalent cross-links. The second mechanism involves non-
covalent interactions of cross-linked domains that are separated by water-soluble 
linkers, and this is usually observed in longer multi-domain structures.68 Tuning of the 
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supramolecular interactions to produce a self-supporting network that does not 
precipitate, and is also able to immobilize water which is vital for to gel formation. Most 
oligopeptide hydrogels have a β-sheet structure, and assemble to form fibers, although 
α-helical peptides have also been reported.69-70 Figure 1.7 shows the typical mechanism 
of gelation where the oligopeptide precursors self-assemble into fibers that become 
elongated, and entangle to form cross-linked gels. 
 
 
 
Peptides based hydrogels possess exceptional biocompatibility and biodegradability 
qualities, giving rise to their wide use of applications, particularly in biomedicine; as 
such, their physical properties can be fine-tuned in order to maximise their use. 
Methods to do this are: modulation of the amino acid sequence, pH, chirality, and 
increasing the number of aromatic residues.71 The order of amino acids within the 
sequence is crucial for gelation, as has been shown many times. In one example, a short 
peptide sequence Fmoc-Phe-Gly readily formed a hydrogel, whereas Fmoc-Gly-Phe 
failed to do so as a result of the two adjacent aromatic moieties being moved, hindering 
Figure 1.7. Simplified scheme to show the self-assembly process involved in hydrogel 
formation. 
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the aromatic interactions.72-73 Altering the pH can also have similar effects, an example 
involved the use of the naphthalene (Nap) modified dipeptides Nap-Gly-Ala, and Nap-
Ala-Gly, where a drop in pH induced gelation of the former, but led to crystallisation of 
the latter.74 A controlled pH decrease method using glucono-δ-lactone (GdL), where the 
GdL is hydrolysed to gluconic acid in water is a recent strategy that has been developed 
as a way to form homogeneous and reproducible hydrogels.75-76 The hydrolysis is slow, 
which allows for a uniform pH change, and thus resulting in reproducible homogenous 
gels. In addition to this, the desired pH can be achieved by altering the amount of GdL 
added. The use of GdL has been used various times for the hydrogelation of Fmoc and 
Nap-dipeptides.75-76 In another direction, Morris et al reported the use of GdL as a 
‘molecular trigger’ to predict and control the order of gelation.77 Chirality also plays 
an essential role in gel formation, and even changing the chirality of a single amino acid 
from its natural L-amino acid to its unnatural D-amino acid can significantly impact the 
gelation properties, with the natural forms not forming gels.78 Furthermore, aromatic 
interactions play a key role in hydrogel formation as a result of π- π stacking driving 
gelation, shown by many studies.79-80 
1.6 Peptide hormones 
 
Peptide hormones are hormones made up of amino acid chains that primarily have an 
effect on the endocrine system. Based on the building units, the hormones can be 
classified as either amino-acid based, or steroid based systems. The former are water 
soluble due to their composition comprising of amino acids, allowing them to act on the 
surface of target cells via secondary messengers. This differs from steroid hormones 
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which are lipid soluble, and so can move through the plasma membranes of target cells 
and act within the nuclei.81  
The endocrine system is composed of many different glands and it can be divided into 
two categories: classical and non-classical. In the endocrine system, hormones are 
secreted into the circulatory system where they are distributed throughout the body, 
regulating bodily functions. The classical endocrine glands include the, pituitary gland, 
pancreas, thyroid gland, adrenal cortex and medulla. The primary function of these 
glands is to manufacture specific hormones. Non-classical endocrine glands include the 
heart, hypothalamus, kidneys, liver, and the gastrointestinal tract. Many of the classical 
hormones are controlled by the hypothalamus and pituitary which can also be classified 
as being an extension of the nervous system.82 
An imbalance of hormones or an inappropriate bodily response to them indicates a 
disorder of the endocrine system, with the most common one being diabetes. There are 
two types of diabetes: type I and type II; the former is due to the pancreas failing to 
produce enough insulin, and the latter is where cells fail to respond to insulin. Type II 
diabetes is associated with obesity, and is therefore controllable with lifestyle choices 
such as diet and exercise.  
 
1.7 Gut-brain interactions 
 
The gut-brain axis allows the two-way communication between the gastrointestinal 
tract (GI) and both the central (CNS) and enteric nervous system (ENS), allowing the 
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body to link emotional and cognitive processes of the brain with peripheral intestinal 
functions.83-84 
Gut-brain interactions are increasingly recognised as playing an important role in 
determining overall food intake.85  Many peptides are synthesised and released from 
the gastrointestinal tract, and it has been shown that they physiologically influence 
eating behaviour via gut-brain signalling.86 Ghrelin is an orexigenic (appetite stimulating) 
peptide produced in the stomach which acts as a meal initiator. This differs from peptide 
YY, Pancreatic polypeptide, glucagon-like peptide 1 (GLP-1), oxyntomodulin, and 
cholecystokinin which are all derived from the intestine and pancreas, and have been 
shown to produce satiety signals. From this it has been suggested that gut hormones 
can be manipulated to regulate energy balance, and as a result gut hormone based 
therapies could be a possible treatment for obesity.86-87 
Although the full mechanism of gut-brain interactions are extremely complex, a vital 
component of the hypothalamic metabolic regulatory circuit is the arcuate nucleus and 
the vagus nerve.86 Vagal afferent neurons express two different neurochemical 
phenotypes that either inhibit or stimulate food intake.88 These are: neuropeptide Y 
(NPY) and agouti-related neuropeptide (AgRP), which act to stimulate food intake and 
pro-opiomelanocortin (POMC) that inhibits feeding. The balance in activity of these 
neuronal circuits is critical to body weight regulation.86 As shown in Figure 1.7, many gut 
hormones have direct access to the hypothalamus, brainstem and vagus nerve. They 
also have a significant impact on feeding in reaction to calorific intake, which is the case 
for  PYY3-36, via Y2 receptors.89 Further discussion of PYY3-36 and Y2 receptors is presented 
in chapter 2. 
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Figure 1.8. Gut-brain axis to show the regulation of food intake. Food is digested and G-
protein coupled receptors are activated, causing gut hormones to be released in the L-
cells of the GI tract. The gut hormones are able to influence food intake via the vagus 
nerve, the brainstem, and the hypothalamus. Within the arcuate nucleus (ARC) of the 
hypothalamus , peripheral signals are given off via neurons (NPY, AgRP, and POMC) to 
stimulate  or inhibit food intake.90  
  
 
1.8 Gastrointestinal peptide hormones  
 
1.8.1 Leptin 
Leptin is a hormone made by adipose cells that affects many biological mechanisms 
including: reproduction, the immune and inflammatory response, haematopoiesis, 
angiogenesis, bone formation, and wound healing. More interestingly however, Leptin 
helps to regulate energy balance by inhibiting hunger. This happens via a feedback 
mechanism where signals are sent to key regulatory centres in the brain to inhibit food 
intake.91  
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After Leptin is released by adipose tissue into the bloodstream, it crosses the blood brain 
barrier (BBB) and binds to the hypothalamic leptin receptors. This affects the activity of 
many hypothalamic neurones, and the expression of various orexigenic (appetite 
stimulating) and anorexigenic (appetite inhibiting) neuropeptides. Orexigenic peptides 
include neuropeptide Y (NPY), and anorexigenic peptides include pro-opiomelanocortin 
(POMC) as mentioned above. It has been suggested that the interaction of both types 
of these neuropeptides is what provides leptin with its mechanism of action in the 
hypothalamus to inhibit hunger.91 
1.8.2 Ghrelin 
Ghrelin is a 28 amino acid peptide with an octanoylated serine residue at position 3,92 
and is produced and secreted by cells within the oxyntic glands (acid secreting glands) 
of the stomach.87 Peripheral administration of ghrelin has been shown to stimulate food 
intake and decrease fat utilization. This means it is involved in energy homeostasis, with 
the serine residue appearing to give ghrelin these effects.92 Ghrelin’s function is unique 
compared to other gut hormones, where it acts to increase food intake rather than 
decrease it, making it a very important component of weight control. A study on mice 
that were lacking ghrelin showed evidence of this and were found to be resistant to diet-
induced obesity when fed a high-fat diet. This was due to them eating less, and therefore 
utilizing more stored fat as an energy source.87 
1.8.3 Cholecystokinin (CCK) 
Cholecystokinin (CCK) is an endogenous gut hormone mainly found in the duodenum 
and jejunum, that exists in several molecular forms with differing numbers of amino 
acids. Examples include CCK-8 and CCK-54 (the number indicates the number of amino 
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acid residues). CCK is known to act as a postprandial satiety signal and it acts via two 
receptors: CCK1 and CCK2. The CCK1 receptor is more important in appetite control.92 The 
receptors are located on the peripheral vagal afferent terminals, which transmit signals 
to part of the brain stem that is associated with appetite, such as the nucleus of the 
solitary tract.87 
1.8.4 Oxyntomodulin (OXM)  
Oxyntomodulin (OXM) is a 37 amino acid peptide expressed in the central nervous 
system and the L cells of the intestine and pancreas.93 OXM seems to mediate its effects 
via the glucagon-like peptide 1 (GLP-1) receptor as shown in experiments carried out on 
rat parietal cells.94 This has been proven by its anorectic actions being blocked when 
administration of the GLP-1 antagonist was carried out.95 Intravenous administration of 
OXM in humans inhibits gastric emptying and gastric acid secretion, which leads to a 
feeling of satiety.96 This feeling of satiety can cause a reduction in both food intake and 
overall body weight, and this is brought about by the suppression of ghrelin.  
1.8.5 Glucagon-like peptide 1 (GLP-1) 
Glucagon-like peptide 1 (GLP-1) is a 30-amino acid gut derived incretin (decreases blood 
glucose levels) peptide hormone,97 meaning that it stimulates insulin secretion in 
response to eating, resulting in suppressed glucagon secretion. In addition to this, GLP-
1 inhibits gastric emptying, and reduces appetite and food intake.98 GLP-1 is produced 
in the intestinal epithelial endocrine L-cells in the distal small bowel and colon by 
differential processing of proglucagon.97-98 Proglucagon is a gene expressed in the L-cells 
and is regulated in the gut and brain.97 Within minutes of food intake, the plasma levels 
of GLP-1 rise rapidly. GLP-1 exists in two circulating molecular forms: GLP-1(7-37) and 
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GLP-1(7-36) amide, with GLP-1(7-36) amide representing the majority of circulating 
active GLP-1 in human plasma. Both forms of GLP-1 are rapidly metabolised and 
inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4) to GLP-1(9-37), or GLP-1(9-
36)amide following the release from gut L cells.99 DPP-4 is a widely expressed enzyme 
that cleaves both forms of GLP-1 at the position 2 alanine of the N-terminal to make 
them inactive. The expression of DPP-4 in the gut and vascular endothelium explains the 
short half-life of GLP-1 of just several minutes, because the majority of immunoreactive 
GLP-1 entering the portal venous circulation has already been inactivated by N-terminal 
cleavage.100 
1.8.6 Pancreatic Polypeptide (PP) 
Pancreatic polypeptide (PP) is a 36-amino acid peptide belonging to the family 
containing neuropeptide Y (NPY) and peptide YY (PYY). All of these peptides are 
members of the PP fold peptide family and they consist of a signal peptide, followed by 
a 36 amino acid active peptide and a carboxyl-terminal.101 The PP fold family bind to 
receptors Y1-Y6, but PP in particular has the highest affinity for the Y4 and Y5 
receptors.92 The Y-receptors belong to the G protein- coupled receptor family, and they 
mediate a wide variety of physiological effects such as regulation of blood pressure, 
anxiety, memory retention, hormone release, and food intake.102 
PP is similar to GLP-1, where it is released into circulation after the ingestion of food, 
except it is produced in the endocrine F cells, located in the periphery of pancreatic 
islets, whereas GLP-1 is produced in the L-cells of the GI tract.103-104 PP is responsible for 
a number of regulatory actions, such as the inhibition of pancreatic exocrine secretion, 
and the modulation of gastric acid secretion, and gastric emptying.105-106 The amount of 
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PP released is affected by the digestive state, i.e. release is very low in the fasted state, 
but is significantly increased throughout all phases of digestion. In addition to this, a 
decrease in blood glucose levels and insulin induced hypoglycaemia are stimuli for PP 
secretion in the brain. As a result, it is thought that PP could potentially play a significant 
role in the regulation of feeding behaviour to control energy homeostasis.103 
1.8.7 Peptide YY 
Peptide YY (PYY) is a gut hormone belonging to the pancreatic polypeptide (PP) fold 
family, along with PP and neuropeptide Y (NPY) as mentioned above. The PP-fold motif 
is found throughout this family and relates to the 3D structure. The PP-fold is formed 
through the incorporation of certain residues which are predominately Pro2, Pro5, Pro8, 
Gly9, Tyr20 and Tyr27. This PP-fold has been found to protect the peptide against 
enzymatic attack as well as producing a hydrophobic pocket which is inherently overall 
energy reducing. In addition to containing the PP-fold motif, PYY and its derivative PYY3-
36 also have a high C-terminal α-helix proportion, suggested to be extremely important 
for the structural integrity of PYY. The sequence of the 36-amino acid peptide, PYY, is: 
Tyr-Pro-Ala-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-AlaSer-Pro-Glu-Glu-Leu-Ser-Arg-Tyr-Tyr-
Ala-Ser-Leu-Arg-His-TyrLeu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2.107 
PYY is released by the L-cells of the gastrointestinal tract following food intake, and there 
are two main endogenous forms: PYY1-36 and PYY3-36. PYY1-36 is rapidly processed by the 
enzyme DPP4 to the 34-amino acid peptide PYY3-36.108 DPP4 hydrolyses PYY and removes 
the first two amino acids, tyrosine and proline, at the N-terminal, which changes the 
receptor selectivity. As a result of this, PYY3-36 has a high selectivity for the Y2-receptor, 
compared to PYY1-36 which has selectivity for the Y1, Y2, and Y5 receptors. It is thought 
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that the Y1 receptor requires both the C-terminus and N-terminus for recognition, 
binding and then subsequent activation. The Y2 receptor is thought to have a smaller 
receptor site and also only requires the C-terminus for recognition (figure 1.8). 
This could explain the reduced affinity for PYY3-36 on any other Y receptor other than 
Y2.109 Other studies replacing the amide bonds with ester bonds also confirm that the 
end section is important in binding and activation.110 The Y2 receptors are located in the 
hippocampus, sympathetic and parasympathetic nerve fibres, intestines, and certain 
blood vessels, and have been implicated in regulating food intake and gastric 
emptying.111 As a result of this, the Y2 receptor is considered a target for the treatment 
of obesity and type II diabetes. 
 
 
 
 
 
 
 
 
Figure 1.9. Illustrations of binding sites for Y1 and Y2 with hPYY + hPYY3-36.109 
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1.8.8 Neuropeptide Y (NPY) 
Neuropeptide Y (NPY) is also a 36 amino acid peptide that has a very similar sequence 
homology to peptide YY (PYY) and PP. NPY differs from the other two peptides however, 
by acting as a neurotransmitter rather than a hormone.112 NPY is one of the most 
abundant peptides found in the brain 113 and it is synthesised and released by neurons, 
which in the peripheral nervous system are mostly sympathetic neurons.112 NPY is 
associated with various biological responses including increased food intake, enhanced 
cognitive function associated with learning and memory, and also reduction in 
anxiety.114 Furthermore NPY has been shown to induce vasoconstriction in peripheral 
blood vessels.115 Studies of NPY and its receptors suggest that it could be directly related 
to various pathological disorders such as obesity, depression and epilepsy.116 
1.9 Peptide therapeutics 
 
There are many peptide therapeutics on the market at present. Due to their high 
specificity, potency, and low toxicity, the number is only going to increase.117-119 Table 
1.1 shows some of the leading peptide therapeutics. Not all of these peptide 
therapeutics self-assemble or are formulated as solutions, but the table shows the 
extent and importance of the use of peptides as drugs.  
The current highest selling marketed diabetic drug Liraglutide, incorporates a lipid chain 
to extent plasma circulation and ensures prolonged bioavailability.120-121 Liraglutide is a 
GLP-1 agonist drug that self-assembles into an alpha-helical structure, and it requires 
once a day administration.122 Lipid conjugation of a palmitoyl chain to a lysine residue 
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at position 26 of Liraglutide results in an extended half-life (around 13-14 hours) in the 
blood. This is due to the palmitoyl chain allowing non covalent binding to albumin, which 
delays proteolytic attack by DPP IV and also rapid renal clearance. Furthermore, the 
addition of the lipid chain could further prolong half-life by sterically hindering the DPP 
IV enzyme from degradation.123 
Another peptide known to self-assemble is the octapeptide, Lanreotide. This compound 
is a synthetic analogue of the peptide hormone somatostatin and it is used to treat 
acromegaly 124 (a condition where the body produced too much growth hormone). In 
water, Lanreotide self-assembles into monodisperse liquid crystalline nanotubes. The 
nanotubes are made up of dimers that self-assemble into a 2D crystal, which is held 
together by lateral chain interactions, and also by antiparallel ß-sheets.124 125 
Further insight into how self-assembly and peptide hormones are related has been 
provided by studies on self-assembling amyloid structures formed by peptide hormones 
and neuropeptides. Peptide hormones and neuropeptides form dense-cored aggregates 
that pack into dense-core vesicles (DCVs), which are used to temporarily store peptide 
messengers in secretory cells.126 When DCVs are triggered, they release the stored 
information into the blood or extracellular space,127 resulting in amyloid disassembly, in 
order for action.126 Therefore for these types of peptides, reversibility of peptide 
aggregation is essential for their function. 
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Table 1.1. Peptide Therapeutics on the Market. 
Trade Name Peptide Company Molecular Properties 
Related 
Reference  
Copaxone Glatiramer Teva 
Four amino acids (L‐glutamic acid, L‐
alanine, L‐lysine, and L‐tyrosine) in a 
defined molar ratio 
128-129 
Lupron Leuprolide Abbott 
Synthetic nonapeptide analogue of 
naturally occurring gonadotropin-
releasing hormone (GnRH or LH-RH) 
130-131 
Vicoza Liraglutide Novo 
97% homologous to native human GLP-1 
(7-37) by substituting arginine for lysine at 
position 34 & addition of a fatty acid chain 
132 
Zoladex Goserelin AZ 
Natural LHRH/GnRH decapeptide with two 
substitutions to inhibit rapid degradation. 
133-134 
Sandostation Octreotide Novartis 
Longer acting synthetic octapeptide 
analogue of naturally occurring 
somatostatin 
135-136 
Forteo Teriparatide Lilly/Amylin 
Recombinant form of parathyroid 
hormone consisting of the first (N-
terminus) 34 amino acids, which is the 
bioactive portion of the hormone 
137-138 
Byetta Exenatide Lilly/Amylin 
Synthetic version of exendin-4, 
a hormone found in the saliva of the Gila 
monster  
139-140 
Cubicin  Daptomycin Cubist 
Cyclic lipopeptide, consists of 13 amino 
acids, 10 of which are arranged in a cyclic 
fashion, and three on an exocyclic tail 
141-142 
Integrilin Eptifibatide Merck 
Cyclic heptapeptide composed with S-S 
bridge, 2 unnatural building blocks and 
amide 
143-144 
Angiomax/Angiox Bivalirudin Medicines 20-amino acid polypeptide 
145-146 
Fortical Calcitonin Upsher-Smith 
32 amino-acid polypeptide similar to 
calcitonin 
147-149 
Somatuline Lanreotide Ipsen 
Cyclic peptide that is a long acting 
analogue of somatostatin.  
150-151 
 
31 
 
1.10   Physical characterisation techniques 
 
1.10.1 Circular dichroism (CD) 
 
Circular dichroism is a spectroscopic technique used to study biological molecules, in 
particular the secondary structure of peptides and proteins. Since secondary structure 
is sensitive to its environment, CD is a good way of observing how secondary structure 
changes with environmental conditions such as temperature and pH. This can then give 
an estimation of its conformation. 
CD is a result of the interaction of polarised light with chiral molecules, and it is defined 
as the unequal absorption of left and right handed circularly polarised light (Equation 
1.1). This occurs because when chiral molecules interact with light, one circularly 
polarised light state is absorbed to a great extent than the other, to produce a CD signal 
that is non-zero.152 Depending on which circularly polarised light (left or right) is 
absorbed more, determines if the CD plot is positive or negative. If the left hand 
circularly polarised light is absorbed to a greater extent, then the signal will be positive 
and vice versa. The absorbance change is written as 
ΔA(λ) = A(λ)LCPL ‐ A(λ)RCPL (Equation 1.1) 
LCPL = left handed circularly polarised light 
RCPL = right handed circularly polarised light 
λ = wavelength  
 
CD spectra in the far UV region (below 260 nm), can be used to measure secondary 
structure, and also predict the percentages of each one present in the molecule. Each 
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secondary structure has distinctive peaks in the spectrum, for example peptides or 
proteins containing α-helices have negative bands at 222 nm and 208 nm, and a positive 
band at 193 nm. Antiparallel β-pleated sheets have negative bands near 216 nm and 
positive bands at 195 nm. Disordered structures have very low ellipticity above 210 nm 
and negative bands at around 195 nm.152 
1.10.2 Fluorescence spectroscopy 
Fluorescence occurs when an electron relaxes back to its ground state from an excited 
singlet state, where it releases a photon in the process. In most cases, the emitted 
photon has a longer wavelength than the excitation wavelength, and therefore a lower 
energy than the absorbed radiation; this is known as the Stokes shift. The Jablonski 
diagram is used to describe the fluorescence mechanism of most molecules by 
illustrating the electronic states of molecules and the transitions between them (Figure 
1.10). When a molecule becomes excited, it transitions from its ground state, S0, to 
either a singlet first electronic excited state, S1 or to a second electronic excited state, 
S2. At each excited energy level, fluorophores have multiple vibrational levels, 
represented by the multiple lines in each electronic state (Figure 1.10). As the molecule 
loses energy and returns to its ground state, S0, a fluorescent photon is released. 
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Figure 1.10. Illustration of the Jablonski diagram to show the mechanism of 
fluorescence.153 
 
Compounds that fluoresce are known as fluorophores and generally they have one or 
more aromatic groups in the structure; although non-fluorescent compounds can also 
fluoresce by the addition of a fluorescent probe containing aromatic structures.  
Fluorescence instruments contain three basic components: a light source, a sample 
holder, and a detector. In fluorescence spectroscopy, a beam is passed through the 
sample in solution at a wavelength ranging from 180-800 nm, and the light emitted by 
the sample is measured by the detector. The light can be measured either by the 
excitation spectrum (light absorbed) or the emission spectrum (light emitted). 
Fluorescence spectroscopy is used to determine the concentration of a compound in 
solution based on its fluorescence properties, and the concentration is directly 
proportional to absorbance, shown by the Beer-Lambert law: A= ε l c, where A is 
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absorbance, ε is the molar extinction coefficient (M-1.cm-1), l is pathlength (cm), and c is 
concentration (M). 
There are several factors that affect the intensity of the fluorescence spectrum, and it 
depends on the excitation wavelength, the concentration of the sample, the pathlength 
of the cuvette, and the self-absorption of the sample.  
1.10.3 Cryo-TEM and TEM 
Transmission electron microscopy (TEM) is a high resolution microscopy technique 
where a beam of electrons is transmitted through a thin sample specimen (<100 nm 
thick), to form an image, as a result of the transmission of electrons through regions of 
the sample with different density. Electrons have a much shorter wavelength than 
visible light, resulting in a resolution limit of a TEM being around a thousand times 
smaller than a light microscope.154 The increased resolution allows structures at the 
nanoscale to be studied, such as bacteria and viruses.  
Electrons are emitted by a negatively charged electron gun (cathode), which may be a 
tungsten filament needle, or a lanthanum hexaboride source. The electrons are 
accelerated by a series of anodes at a high voltage and under vacuum to reduce the 
amount of electrons colliding with the air. Typical voltages used range from 60-200 kV 
depending on the type of sample, but for biological samples a range of 60-100 kV is used 
to reduce the amount of sample damage.  
TEM instruments use a range of electromagnetic lenses which consist of copper coil 
wires inside iron pole pieces, to create an electric field, and they help to focus the 
electron beam and magnify the image. There are three main lenses: the condenser lens, 
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the objective lens, and the projector lens. The condenser lens is used to focus the 
electron beam onto the specimen, the objective lens is used primarily to focus and 
initially magnify the image. Finally the projector lens is used to further magnify the 
image and project it onto the imaging device such as a CCD camera. 
Apertures are also used in TEM to decrease the beam intensity, and to remove electrons 
that are scattered to high angles, as a result of spherical or chromatic aberration, or 
from diffraction.155 The condenser aperture is used to control the fraction of the beam 
that is allowed to hit the sample, and the objective aperture is used to select which 
beams in the diffraction pattern contribute to the image, thus producing a diffraction 
contrast. 
The electrons that pass through the sample can be diffracted by crystalline samples, 
resulting in diffraction patterns that give information about the crystal structure of the 
sample. Using a TEM in diffraction mode can be used in conjunction with X-ray 
diffraction to determine crystal structures. 
Sample preparation can be quite complex in TEM, especially for biological samples as 
they often require negative staining to increase the contrast (electron density 
difference), and reveal the structure. Negative staining involves the surrounding of 
biomolecules with a thin layer of a heavy metal salt such as uranyl acetate. 
Cryogenic transmission electron microscopy (cryo-TEM) uses the same technique as 
TEM but at cryogenic temperatures. Aqueous samples are plunge frozen in liquid 
ethane, allowing the structure of biomolecules in solution to be determined without the 
need for crystallisation.  
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1.10.4 Small angle X-ray scattering 
Small angle X-ray scattering (SAXS) is a small angle scattering technique used to 
investigate the shape and size of nanostructures from 1-100 nm in a typical set up, with 
a scattering angle ranging from 0.1-10 o. In a SAXS instrument a monochromatic beam 
of X-rays is sent through a sample, where some interact and are scattered by the sample 
to produce a scattering pattern containing information on the structure. By measuring 
the angle-dependant distribution of the scattered intensity, the average particle 
structure can be determined.156 
There are five main basic components of a SAXS instrument: an X-ray source, a 
collimation system, a sample holder, a beam stop, and a detection system. The X-ray 
source irradiates the sample and in lab based systems this is usually a sealed X-ray tube, 
a microfocus X-ray tube, or a rotating anode. Synchrotron facilities are often favoured 
though as they can provide a higher flux and can provide X-rays of all wavelengths as a 
result of the production of Bremsstrahlung, therefore producing a continuous 
wavelength spectrum. The collimation system is used to narrow the beam, reducing its 
intensity. There are two types of collimation: point collimation, where the beam is 
shaped to a small circular or elliptical spot, and line collimation where the beam is 
confined only in one dimension to give a long but narrow beam. This results in a larger 
illuminated sample volume and a bigger scattered intensity. The sample holders vary 
significantly depending on the type and state of sample being measured, and usually 
they are handmade. The function of the beam stop is to protect the detector from being 
damaged by the X-ray beam, and the detection system can be wire detectors, CCD 
detectors, imaging plates, and solid-state detectors.  
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Scattered radiation can have the same wavelength or a different wavelength than the 
incident radiation, as a result of scattering being able to occur with or without the loss 
of energy. Scattered radiation that has a different wavelength is known as inelastic 
scattering, such as Compton scattering, and scattered radiation with the same 
wavelength as the incident radiation is known as elastic scattering, such as Rayleigh or 
Thomson.157 SAXS analyses elastic scattering at small angles. 
The interaction of X-rays with the structure produces an interference pattern at the 
detector, which are either constructive (in phase), or destructive (out of phase), 
depending on the observational angle 2θ, the orientation, and the distance r of the 
atoms from each other. In constructive interference, a bright spot is produced at the 
detector, whereas for destructive interference the radiation waves extinguish each 
other, producing a dark spot at the detector. The result is a 2D interference pattern, 
characteristic to the internal structure of the sample to give information on the 
orientation and distances of atoms relative to one another. The scattering angle (2θ) 
depends to the wavelength of the applied radiation through Bragg’s Law. To overcome 
this and become independent from the wavelength the scattering pattern is presented 
as a function of q (length of the scattering vector), where q =  
4π sinθ
λ
 with units of nm-
1. Form factors give information about the shape of particles, but require the particles 
to be in a dilute system where they can be considered as independent scatters without 
any interactions. The form factor also assumes that particles are monodisperse, but if 
they are polydisperse, then an average scattering pattern of all of the different sizes are 
obtained.158 
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In more concentrated systems where the particles are densely packed, the distances 
between the particles become similar to the distances inside the particles. This results 
in the interference pattern containing contributions from the neighbouring particles. 
The addition of this interference is multiplied with the form factor of a single particle to 
become the structure factor. The structure factor therefore contains information about 
the positions of particles with respect to each other and is calculated using the equation: 
I(q) = P(q)S(q), where I(q) is the intensity as a function of q, P(q) is the form factor, and 
S(q) is the structure factor.159 An increase in intensity generally indicates an attractive 
interaction, suggesting aggregation of particles. When particles aggregate they can align 
into an ordered arrangement to create a crystalline structure, creating distinct peaks in 
the scattering intensity profile. These are known as Bragg peaks, and using Bragg’s law 
it is possible to determine the distance, d, between aligned particles: d = 2π/q.160 
1.10.5 Fibre X-ray diffraction 
Fiber X-ray diffraction (XRD) is a form of X-ray scattering used to determine the 
structural information of a molecule, by the production of a fibre pattern from the 
scattered X-rays. The technique is suitable for investigation of samples that form fibres 
or stalks, and as such is used to investigate amyloid and related peptides.161-162 This 
technique is similar to SAXS, except the sample-detector distance is shorter, thus giving 
diffraction patterns at wider angles. Similar to SAXS, the distance between the regularly 
spaced atoms in a crystalline structure can be measured by determining the d-spacing 
using Bragg’s law. In fibre diffraction the sample has cylindrical symmetry around an axis 
(the fibre axis) and the ideal fibre pattern contains 4-quadrant symmetry, where the 
fibre axis is called the meridian and the perpendicular direction is called the equator. An 
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example of an orientated and un-orientated fibre diffraction pattern is shown in Figure 
1.11 by the Serpell group.163 
 
 
 
 
 
 
 
 
 
Figure 1.11. Fibre diffraction pattern of amyloid fibrils. a) orientated sample, b) un-
orientated sample.163 
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1.11 Aims 
 
The overall aim of the research conducted in this thesis is to investigate the self-
assembly of lipidated derivatives of the gastrointestinal peptide hormone, PYY3-36, and 
truncated fragments of it, with changes in temperature, pH, and concentration. The 
results are then compared with the native peptides, to understand the impact of 
lipidation on self-assembly. The idea is to develop a further understanding of lipidation 
as a potential chemical modification tool, to increase the stability of peptide based 
drugs, which in this case is for use in obesity and type II diabetes treatment.  
More specifically, the aims are: 
 To investigate the self-assembly of PYY3-36, and three lipidated derivatives, with 
palmitoyl chains attached via a γ-glutamic acid spacer, to a lysine residue on the 
peptide at positions 11, 17, and 23. 
 To investigate the possibility of hydrogel formation of PYY3-36, and the three 
lipidated derivatives. 
 To investigate the self-assembly of various N-terminal truncated fragments of PYY3-
36, and understand the impact of lipidation with palmitoyl chains on the self-
assembly. 
 To study the possibility of hydrogel formation of the truncated fragments and their 
lipidated derivates. 
 To understand the use of a PYY3-36 truncated lipidated fragment with a free proline 
residue (PAEPKI-NH-C16H33) as a catalyst in aldol reactions. 
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 To carry out cytotoxicity assays on the truncated PYY3-36 peptides, using a human 
colon cancer cell line (HCT-116), to understand the impact of lipidation on toxicity. 
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Chapter 2 - Effect of Lipidation and Position of Lipidation on the 
Self-Assembly of the Gastrointestinal Peptide Hormone PYY3-36 
 
2.1 Introduction 
Peptide YY (PYY) is a gut hormone released by the L-cells in the gastrointestinal tract 
following food intake. There are two endogenous forms: PYY1—36, and PYY3-36, with the 
latter having a high selectivity for the Y2 G-coupled protein receptors, associated with 
reduced food intake via the vagal inhibitory loop.1 The vagus nerve plays an important 
role in controlling metabolism, by communicating with the gut via cell-signalling to 
understand its nutritional status. This allows the stimulation or inhibition of food intake 
depending on the feeding status. Unfortunately, the sensitivity of this mechanism is 
reduced when chronic calorie overload occurs, which helps to drive obesity.2 Studies of 
PYY3-36 in humans and mice have shown it to significantly reduce calorific intake.3-6 This 
makes PYY3-36 an attractive agent for the treatment of obesity and type II diabetes. One 
major downfall is its short half-life of around 9 minutes, due to rapid clearance from 
circulation as a result of low molecular weight.7 Peptide lipidation to overcome this issue 
would allow the peptide to non-covalently bind to serum albumin, increasing the 
molecular weight substantially, protecting the whole complex from proteolytic 
degradation.8 
Previous self-assembly studies of PYY3-36 have shown it to adopt a predominant α-helical 
secondary structure.9 Here, we use a range of spectroscopic, scattering, and microscopy 
techniques to further investigate the self-assembly of PYY3-36, and how lipidation 
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impacts the self-assembly. Three lipidated derivatives of PYY3-36 and the peptide itself 
were examined, to determine whether lipidation has an impact on the self-assembly 
and aggregation, as a result of the increased amphiphilicity caused by lipidation. 
Palmitoyl chains were covalently attached to the peptides, by substitution of γ-L-
glutamoyl(Nα-hexadecanoyl) lysine residues at position 11 (PYY11), 17 (PYY17), or 23 
(PYY23) as shown in Figure 2.1. Unlipidated PYY3-36 was characterized using the same 
techniques, and shown for comparison (Figure 2.2). Characterisation of PYY17 in 
solution was carried out by PhD student Sam Burholt (University of Reading), but results 
are included here to allow a full comparison between lipidation points. 
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Figure 2.1. a) Sequence and structure of PYY 3-36 with the positions of lipidation shown 
by the arrows.10 b) Scheme of PYY 3-36 showing the three lipidation positions, 11 (PYY11), 
17 (PYY17), and 23 (PYY23). At each lipidation position, the amino acid present (Ser or 
Arg) is replaced with a lysine derivative in which the alkyl chain is attached via a γ –L- 
glutamic acid spacer. 
 
 
Figure 2.2. Scheme of PYY 3-36. 
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2.2 Results and Discussion 
 
2.2.1 Solution studies 
 
Fluorescence assays using pyrene and Thioflavin T (ThT) as the fluorescent probes, were 
carried out to investigate the presence of a critical aggregation concentration (cac). 
Pyrene is a fluorophore that is sensitive to the local hydrophobic environment, 11 and 
has been successfully used previously to determine the cac of peptides and peptide 
amphiphiles.12-13 In the presence of micelles and other macromolecular systems, it 
becomes encapsulated in the interior regions of the aggregates.11 This allows the cac to 
be determined, because upon aggregation, hydrophobic sites are formed that interact 
with the fluorescent probes. As a result there is a distinct break in intensity of 
fluorescence which defines the cac. ThT is selective towards amyloid fibril structures,14-
15 and upon binding, there is a distinct increase in fluorescence intensity, similar to 
pyrene.16 The exact binding mechanism of ThT is not yet fully understood, but it is 
thought that amyloid fibrils provide a ThT binding site that sterically traps the bound 
dye, leading to an increase in fluorescence.17  
Pyrene was used to determine the cac of the three lipidated peptides, and it was 
calculated by measuring the fluorescence intensity of the I1 (λ= 373 nm) peak, 
corresponding to the first vibronic band of pyrene. A plot of I1 (373 nm) intensity with 
concentration is presented in Figure 2.3 to show the cac of all three peptides at native 
pH in ultrapure water (pH 4). The native pH is defined as the pH of the solution when 
the peptide is dissolved in ultrapure water. The fluorescence intensity shows breaks at 
0.013, 0.015, and 0.0091 wt % (± 0.005 wt %), indicating these as the cac values for 
PYY11, PYY17, and PYY23 respectively. The pH dependence of the cac was also 
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investigated using pyrene. Plots of I1/I3 [I (373 nm)/I (383 nm)] corresponding to the 
ratio of the intensities of the first to third vibronic bands of pyrene are shown in Figure 
2.4, as well as plots of I1 (373 nm). Plots of I1/I3 for PYY11 were not well-defined 
throughout the pH range studied, or for PYY23 at pH 2. As a result, only plots of I1 (373 
nm) for PYY11 in the pH range 2-8, and PYY23 at pH 2 are shown to define the cac values 
(Figure 2.4). From previous studies using other fluorescent probes to compare to 
pyrene, the concentration dependence of I1 provides a reliable assay for cac values.12-
13, 18 Results indicate that the cac values are lower for the peptide solutions at native pH 
compared to pH 2 and 8, suggesting a decrease in hydrophobicity when the pH is altered 
from the native pH. Table 2.1 summarises the cac values of all 3 peptides as a function 
of pH. 
Figure 2.3. Pyrene fluorescence intensity of I 1(373 nm) as a function of concentration, 
for PYY11, PYY17, and PYY23 at native pH (pH 4). The intersections of the lines defines 
the cac.  
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Figure 2.4. Concentration dependence of pyrene fluorescence of PYY11, PYY17, and 
PYY23 in the pH range 2-8 to determine the cac. The intersections of the lines defines 
the cac. a) I1(373 nm) as a function of concentration, for PYY11 in the range pH 2-8. b) 
I1/I3 as a function of concentration, for PYY17 in the pH range 2-8 (vibronic band = I(373 
nm)/I(383 nm)). c) I1 (373 nm) as a function of concentration, for PYY23 at pH 2. d) I1/I3 
as a function of concentration, for PYY23 at pH 4 and 8. 
  
Table 2.1. Cac values of PYY11, PYY17, and PYY23 in the pH range 2-8 at 20 o C. 
 
  
 
 pH 2 (wt%) pH 4 (native pH) (wt%) pH 8 (wt%) 
PYY11 0.0038 0.013 0.023 
PYY17 0.0704 0.012 0.0595 
PYY23 0.012 0.0093 0.033 
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Fluorescence using Thioflavin T (ThT) as the probe was used for PYY3-36, since pyrene 
proved to be unsuccessful in defining a cac. This could be due to the peptide not having 
enough hydrophobic sites for pyrene to bind to. The distinct breaks in intensity to define 
the cac values occur at 0.046 wt% and 0.022 wt% for pH 6, and pH 8 respectively (Figure 
2.5). No cac was observed for PYY3-36 at pH 2, suggesting a lack of amyloid formation at 
low pH. This indicates that the unlipidated peptide is not stable to changes in pH when 
compared to the lipidated peptides. 
 
Figure 2.5. Thioflavin T fluorescence intensity of I max (488 nm) as a function of 
concentration of PYY3-36 at pH 6 (native pH) and pH 8 to define the cac. 
 
Titrations were carried out to determine the isoelectric point (pI) of each peptide 
because calculated values were significantly different from the point at which 
precipitation was observed. Precipitation occurred at around pH 6 for the lipidated 
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peptides, therefore this was tentatively associated with experimental pI. Experiments 
were carried out using 2 wt% peptide solutions and the starting pH was pH 10, following 
the addition of NaOH. The pH was plotted as a function of added volumes of HCl, where 
HCl was added dropwise. The plot indicates that the pH shows an initial sharp decrease 
with a plateau at around pH 5, close to the pH at which precipitation occurred. This is 
associated with an effective pI (Figure 2.6). The exact isoelectric point of each peptide 
was not able to be measured from the titration graph due to the range of pKa values of 
the residues within the peptide sequences.  
Figure 2.6. pH titrations using HCl to show pKa transitions. 
 
It is known that the pKa values of ionisable groups in proteins can vary substantially 
from their expected values when in the folded state. This depends on three main 
environmental factors; The Born Effect (dehydration), Coulombic interactions (charge- 
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charge interactions), and hydrogen bonding.19-20 The Born effect allows for pKa values 
of Asp, Glu, Cys, and Tyr to increase, and those of His, Lys, and Arg to decrease if they 
are buried within a folded protein. This is due to it being energetically unfavourable to 
transfer a charged group from water to the interior of a protein where the dielectric 
constant is lower. Coulombic interactions follow Coulomb’s law where an energy 
minimum is reached depending on the distance between charges. This can result in 
amino acids becoming polarized, and cause pKa values to change. Hydrogen bonding 
affects pKa depending on whether the hydrogen bonding interactions are more 
favourable in the protonated or deprotonated state. For the former, the pKa values will 
increase, and for the latter they will decrease. All three of these environmental factors 
can cause pKa values to change by several units.21 An experiment to look at pKa shifts 
of lysine residues within SNase with pH change was carried out by Isom et al, and they 
remarkably found that the values were lowered by more than 5 units, some of the 
largest shifts in pKa ever measured.20 
Zeta potential measurements were also carried out to further investigate the particle 
charge with varied pH. Studies were performed in the pH range 2-4, and results 
indicated a positive charge on all 3 lipidated peptides under these conditions (Table 2.2). 
 
Table 2.2. Zeta potential values of PYY11, PYY17 and PYY23, at pH 2 and 4. 
Sample pH  Zeta Potential                    
(mV) 
Mobility         
(µm cm/V s) 
Conductivity        
(mS/cm) 
PYY11 2 44.43 3.48 1.93 
PYY11 4 33.57 2.63 0.065 
PYY17 2 42.63 3.34 1.91 
PYY17 4 16.47 1.29 0.053 
PYY23 2 41.10 3.22 4.89 
PYY23 4 20.00 1.57 0.031 
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The secondary structures of PYY3−36, PYY11, PYY17, and PYY23 were examined using 
circular dichroism (CD) spectroscopy well above the cac values. Temperature ramp 
experiments were carried out at pH 2, 4, 6, and 8 from 20 to 70 °C. Figures 2.7-2.8 show 
CD spectra of all peptides in the pH range 2−8 at 20 °C and 70 °C. The spectra at 20 °C 
for all samples studied show two minima near 222 and 208 nm, and these features are 
typical of α-helical secondary structure, and are consistent with coiled coil formation.22-
24 When increasing the temperature to 70 °C, there appears to be a transition into β-
sheet above 50 °C for PYY17 and PYY23 at pH 8, with a minimum near 217 nm, 
characteristic of β-sheet secondary structures (Figure 2.9).22-24 This transition could be 
related to the lower theoretical isoelectric point for PYY17 and PYY23 compared to 
PYY11 and PYY3−36. At pH 8, PYY17 and PYY23 are expected to have a charge of +2, and 
PYY11 and PYY3-36 are expected to have a charge of +3, meaning that there are only weak 
interactions to overcome in order to aggregate, and that hydrogen bonding can more 
readily overcome the electrostatic interactions to form a β-sheet structure.25 
Interestingly, PYY11 does not undergo this transition, which suggests that the position 
of lipidation causes a difference in the stability of the secondary structures. It seems 
that lipidating the peptide outside of the α-helical region of the molecule reduces the 
tendency for β-sheet formation at high pH. PYY3−36 does not undergo this transition 
either, suggesting that the increased amphiphilicity of the lipidated peptides PYY17 and 
PYY23 influences the secondary structure, at higher pH. The lower stability of PYY3−36 to 
temperature changes is also shown by the significant decrease in molar ellipticity upon 
heating (Figure 2.10). 
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Figure 2.7. CD spectra of 0.5 wt% solutions of PYY11, PYY17, PYY23, and PYY3-36 at 20 °C. 
a) pH 2, b) native pH (pH 4 for lipidated peptides, and pH 6 for unlipidated peptide), c) 
pH 8. 
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Figure 2.8. CD spectra from 0.5 wt% solutions of PYY11, PYY17, PYY23, and PYY3-36 at 70 
°C. a) pH 2, b) native pH (pH 4 for lipidated peptides, and pH 6 for unlipidated peptide), 
c) pH 8. 
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Figure 2.9. Temperature ramp CD spectra using 0.5 wt% solutions of PYY11, PYY17, 
PYY23, and PYY3-36 from 20-70 °C at pH 8 to show α-helix to β-sheet transition. a) PYY11, 
b) PYY17, c) PYY23, d) PYY3-36. 
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Figure 2.10. Temperature ramp CD spectra using 0.5 wt% solutions of PYY11, PYY17, 
PYY23, and PYY3-36 from 20-70 °C at native pH (pH 4 for lipidated peptides and pH 6 for 
unlipidated PYY3-36 in ultrapure water. a) PYY11, b) PYY17, c) PYY23, d) PYY3-36. 
 
The α-helix content was calculated based on a molar ellipticity value reported for an 
infinite length 100% helical peptide, where [Θ] = −37,400 deg cm2 dmol−1.26-27 The 
results indicate that the position of lipidation does not appear to affect the secondary 
structure, apart from PYY11 at pH 8 where the α-helix content is significantly decreased 
(Figure 2.11). The calculated α-helical content of the peptides is summarized in Table 
2.3. Apart from PYY11 at pH 8, each lipidated peptide shows a reduced dependence of 
α-helix content on pH and temperature compared to PYY3−36. This useful result shows 
that lipidation enhances the stability of the peptides α-helical domain to changes in pH 
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and temperature. The results in Figure 2.11 also show that PYY23 has the highest α-
helical content out of all three lipidated peptides studied throughout the whole pH and 
temperature range. This is the peptide which is lipidated in the core of the α-helical 
domain (Figure 2.1a). 
 
 
 
 
 
 
Figure 2.11. Calculated α-helix content of PYY3-36, PYY11, PYY17, and PYY23 at; a) pH 2, 
b) the native pH of the peptide (pH 4 for lipidated peptides and pH 6 for native PYY3-36, 
and c) pH 8, 20-70 °C. 
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Table 2.3. Calculated α-helix content of PYY3-36, PYY11, PYY17, and PYY23 at pH 2, native 
pH in ultrapure water (pH 4 for lipidated and pH 6 for unlipidated peptide), and pH 8, at 
20 °C. 
 
 
The aggregation morphology of all 4 peptides was examined in the pH range 2-8, using 
SAXS and cryo-TEM, to investigate the impact of lipidation. Cryo- TEM avoids the need 
to dry or stain the sample, by vitrifying the solution. Images of all three lipidated 
peptides in the pH range 2-8 are shown in Figures 2.12-2.15. The images indicate the 
presence of long entangled fibers with some globular objects, with variable lengths of 
several hundred nanometres for PYY11 at pH 8, PYY17 at pH 2−8, and PYY23 at pH 4 and 
pH 8. Although the fibril length cannot be accurately determined at these 
magnifications, the fibril radius is measured as 8.0 nm (±1.6 nm) at pH 4, and 2.9 nm 
(±0.5 nm) at pH 8 for PYY17, and 8.2 nm (±1.6 nm), and 2.7 nm (±0.5 nm) at pH 4 and 8, 
respectively, for PYY23. Accurate radius values of PYY11 fibrils could not be measured 
due to the entangled nature of the structures. However, the radius was observed to be 
Helix Content (%) at 20 
o C 
pH 2  pH 4 
(native pH in ultrapure 
water)             
pH 8 
PYY3-36 19.9 43.3 36.3 
PYY11 29.9 35.3 15.5 
PYY17 21.4 35.0 33.5 
PYY23 30.5 37.3 36.6 
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approximately less than 10 nm. Images of PYY11 at pH 2 and 4, and PYY23 at pH 2 show 
the appearance of micelles with an average radius of 4.8 nm (±0.7 nm) and 3.7 nm (±0.8 
nm) for PYY11, and 23 respectively. It is also very interesting to see that the position of 
lipidation affects the aggregated structure at pH 2, where PYY17 forms fibers, and PYY11 
and PYY23 form micelles. This is presumably due to enhanced electrostatic interactions 
between charged residues in PYY11 and PYY23. The native peptide forms twisted 
nanotapes (Figure 2.15); it is thus clear that lipidation causes a change in aggregation, 
especially at low pH. 
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Figure 2.12. Cryo-TEM images of PYY11, 0.5 wt% in H2O. a) pH 2, b) pH 2, c) pH 4 (native), d) pH 
4 (native) e) pH 6, f) pH 6 g) pH 8, h) pH 8. 
a) b) 
c) d) 
e) f) 
g) h) 
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Figure 2.13. Cryo-TEM images of PYY17, 0.5 wt% in H2O. a) pH 2, b) pH 2, c) pH 4 (native pH), d) 
pH 4 (native pH), e) pH 6, f) pH 6, g) pH 8, h) pH 8. 
c) 
b
) 
c) 
e) 
g) h) 
d) 
f) 
a) b) 
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Figure 2.14. Cryo-TEM images of PYY23, 0.5 wt% in H2O. a) pH 2, b) pH 2, c) pH 4 (native pH), d) 
pH 4 (native pH), e) pH 6, f) pH 6, g) pH 8, h) pH 8. 
c) 
a) b) 
d) 
g) 
e) f) 
h) 
72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15. Cryo-TEM images of PYY3-36, 0.5 wt% in H2O. a) pH 2, b) pH 4, c) native pH (6.15), d) 
native pH (6.15), e) pH 8, f) pH 8. 
 
 
f) 
a) b) 
 e) 
d) c) 
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Cryo-TEM was complimented with SAXS, which provides accurate dimensions and 
internal structures of the nanostructures. The SAXS intensity profiles for PYY11, 17, and 
23 are shown in Figure 2.16. The data for PYY3−36 is shown in Figure 2.17. The scattering 
data can be fitted to a spherical shell form factor for PYY11 at pH 2 and 4 and for PYY23 
at pH 2. A long cylindrical shell form factor was used to fit the remaining data for the 
lipidated peptides. SAXS data of the native peptide, PYY3−36 was fitted to a generalized 
Gaussian coil at pH 2 and 6. This form factor is used to represent isolated peptide 
unimers in solution. Although cryo-TEM images show a population of twisted 
nanotapes, the SAXS profiles are dominated by unimers. The data at pH 8 was fitted to 
a bilayer Gaussian form factor which is used to represent nanotape structures. Despite 
the Cryo-TEM images of PYY3−36 at pH 8 showing aggregated clusters, the SAXS data 
indicates the presence of nanosheets. This is in contrast to the lipidated peptides, 
suggesting that lipidation significantly changes self-assembly throughout the whole pH 
range (pH 2−8). The fitted parameters are listed in Tables 2.4-2.7. The fittings were 
carried out using the software SASfit.28 A notable observation when comparing SAXS 
data of the lipidated peptides across the whole pH range is the difference in radius (R) 
and shell thickness (DR) values (Figure 2.18). Changing the pH of PYY17 away from its 
native pH caused the radius to decrease, whereas for PYY23 the opposite occurred, 
whereby increasing the pH caused the radius value to increase. As the pH was raised 
from 2 to 8, the shell thickness for PYY17 also increased. 
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Figure 2.16. SAXS intensity profiles. a) PYY11, b) PYY17, c) PYY23 at pH 2-8. All samples 
were at 0.5 wt% and 20 °C. PYY11 data was fit to a spherical shell form factor at pH 2 
and 4, and a long cylindrical shell form factor at pH 8. PYY17 data was fit to a long 
cylindrical shell form factor for all pH values. PYY23 was fit to a spherical shell form 
factor at pH 2 and a long cylindrical shell form factor at pH 4 and 8. 
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Table 2.4. SAXS form factor parameters of PYY11, and PYY23 at pH 2 and 4 at 0.5 wt% 
fit to a spherical shell form factor model using SASfit. Key: BG = background. N= scaling 
factor. σ = Gaussian width. R1= inner radius. R2 = outer radius. μ = scattering contrast of 
inner core. η = scattering contrast of shell. 
 
 
 
 
 
 
 
 
 
 
 
 
Sample BG N / arb. 
units 
σ/ nm R1 / nm R2 / nm µ η 
PYY11 pH 2 1.24 1.83 0.834 1.69 0.826 -1.89 0.156 
PYY11 pH 4 0.180 0.323 0.503 2.31 0.851 -1.30 0.137 
PYY23 pH 2 0.900 1.93 0.502 2.06 0.771 -1.34 0.126 
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Table 2.5. SAXS form factor parameters of PYY11, PYY17, and PYY23 at pH 2, 4, and 8 
and 0.5 wt% fit to a long cylindrical shell model using SASfit. Key: BG = background. N = 
scaling factor. σ = Gaussian width. R = inner radius. DR =shell thickness. L = length of 
cylinder. ηcore= scattering contrast of core. ηshell= scattering contrast of shell. ηsolv= 
scattering contrast of solvent. 
 
 
 
 
 
 
Sample BG N / 
arb. 
units 
σ/ 
nm 
R / 
nm 
DR / 
nm 
L / 
nm 
ηcore ηshell ηsolv 
PYY11 
pH 8 
1.8 0.120 0.261 1.33 0.250 500 0.0212 0.218 0.0162 
PYY17 
pH 2 
0.9 0.258 0.286 1.27 0.113 500 0.0357 0.312 0.0314 
PYY17 
pH 4 
0.9 0.267 0.321 1.63 0.151 500 0.0408 0.241 0.0185 
PYY17 
pH 8 
0.8 0.286 0.347 1.45 0.271 500 0.0469 0.165 0.0266 
PYY23 
pH 4 
0.514 0.333 0.283 1.41 0.126 500 0.0322 0.285 0.0242 
PYY23 
pH 8 
2.4 0.197 0.776 2.55 0.209 500 0.0570 0.180 0.0308 
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Figure 2.17. SAXS data and form factor fittings of PYY3-36 in the pH range 2-8. pH 2-6 was 
fitted to a generalized Gaussian coil form factor, characteristic of unimers. pH 8 data 
was fitted to a bilayer Gaussian form factor to represent nanosheet structures. 
 
 
Table 2.6. SAXS form factor parameters of PYY3-36 at pH 2-6 and 0.5 wt% fit to a 
generalized Gaussian coil form factor model using SASfit. Key: BG = background. N= 
scaling factor. Rg = radius of gyration. ν = Flory exponent. I0= forward scattering. 
 
 
Sample BG N / arb. units Rg / 
nm 
ν I0 
PYY3-36  
pH 2 
0.700 0.100 1.69 0.278 198 
PYY3-36  
pH 4 
0.750 0.152 1.87 0.254 205 
PYY3-36  
pH 6 (native 
pH) 
0.0207 1.00 22.1 0.295 0.0842 
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Table 2.7. SAXS fitting parameters of PYY3-36 at pH 8 and 0.5 wt% fit to a bilayer Gaussian 
form factor. BG = background. N = scaling factor. σ = Gaussian width. t = bilayer 
thickness. σout= Scattering density of outer Gaussians. bout = width of outer Gaussians. 
σcore = scattering density of inner Gaussian. bcore = width of inner Gaussians D = diameter 
of disc (fixed parameter). 
 
 
Figure 2.18. Radius R and shell thickness DR versus pH for PYY11, PYY17, and PYY23 
using a long cylindrical shell form factor fitting from SASfit. 
 
 
Sample BG N / 
arb. 
units 
σ/ 
nm 
t/ 
nm 
σout bout σcore bcore D/ 
nm 
PYY3-36 
pH 8 
2.09 1.39 1.74 3.19 0.597 8.62x10-
4 
3.59 -1.35x10-4 1000 
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2.2.2 Hydrogel Studies 
 
Hydrogels have many useful properties for use in therapeutic applications such as drug 
delivery and tissue engineering. Limited studies have been reported on lipidated 
peptide hydrogels thus far, in particular α-helical peptides. Some studies have been 
reported for lipidated β-sheet forming peptides, where a network of non-covalently 
cross-linked fibers under favourable conditions lead to gelation.29-31 Since cryo-TEM and 
SAXS of the lipidated PYY3-36 peptides indicated the formation of fibers under 
appropriate pH conditions, it was of interested to examine their gelation properties. 
Studies were carried out in the pH range 2-9 to understand the impact of pH on gelation, 
and the native peptide was also studied to allow for comparison. Experiments to 
discover the possibility of gel formation of PYY17 and PYY23 were carried out by Sam 
Burholt, but the table of parameters are included here to allow for a full comparison. 
Interestingly, all three lipidated peptides formed hydrogels at pH 8, the pH at which a 
thermal transition from α-helix to β-sheet occurred in solution. Contrary to this, gelation 
of PYY3-36 was not observed throughout the pH range studied, highlighting the 
importance of the thermal transition, amongst other parameters, for gel formation. The 
pH values at which gels were observed are listed in Table 2.8 and representative images 
are shown in Figure 2.19. Results indicate that it is possible to form hydrogels by a simple 
pH adjustment from the peptides native pH, with heating. An interesting observation is 
that PYY11 only gelates at around pH 8, whereas the other two lipidated peptides 
formed hydrogels at pH 3, 6, and 7 also. At pH values close to pH 6, all three lipidated 
peptides formed precipitates, suggesting that this pH is close to the PI of the peptides 
as discussed previously, which may influence gelation. The reason for gelation not 
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occurring between pH 4 and 6 may be the increased charge on the peptides in this pH 
range due to the pKa values of the charged residues. This is very hard to quantify 
because the pKa in peptides can shift upon aggregation.32-33  
Table 2.8. pH values at which gelation occurred for the lipidated peptides. 
Successful pH values for gel formation (± 0.01) 
PYY11 PYY17 PYY23 
pH 8.47 pH 3.80 pH 3.19 
pH 8.76 pH 7.35 pH 6.09 
 pH 7.77 pH 6.11 
 pH 8.67 pH 6.56 
 pH 8.88 pH 7.16 
  pH 8.57 
No gels formed from unlipidated PYY 3-36 
 
 
 
 
 
Figure 2.19. Gels formed by the lipidated peptides at pH 8. a) PYY11 b) PYY17, c) 
PYY23. 
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CD and fiber XRD were used to investigate gel conformation, along with SAXS and TEM 
to understand the morphology. Polarized optical microscopy (POM) was also used to 
observe green birefringence from binding of the dye Congo red to amyloid fibrils. Gel 
CD studies were carried out at pH 8, the pH at which all three lipidated peptides formed 
gels. Results (shown in Figure 2.20) show a β-sheet secondary structure, with a 
minimum near 217 nm. These results are distinctly different to the peptides in solution, 
where an α-helical structure was observed below 50 °C. Above 50 °C, a thermal 
transition from α-helix to β-sheet occurred as mentioned above. An interesting point to 
note is that at pH 6, PYY17 did not form a gel, but the CD data still shows β -sheet 
structure with a minimum at 217 nm (Figure 2.20a). As a result, it is suggested that the 
factors behind gelation a combination of pH change, and a thermal transition from α- 
helix to β-sheet. 
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Figure 2.20. Temperature-dependent circular dichroism spectra at 2 wt% of: a) PYY17 
pH 5.98, b) PYY17 pH 8.88, c) PYY23 pH 6.09, d) PYY23 pH 8.60. 
 
The thermal transition from α-helix to β-sheet of PYY11 was examined using CD at pH 8 
(Figure 2.21). The experiment was carried out using a 2 wt % peptide solution and this 
pH was chosen as the pH at which all lipidated peptides formed the strongest gels. The 
pH was changed using NaOH (0.5 M) and HCl (0.5 M). The sample was heated in a water 
bath at 60 °C and measurements were taken every 20 min until the transition occurred. 
The results show that the transition started to occur at 60 minutes and after 80 minutes 
the structure was fully β-sheet with a minimum at 218 nm.  
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Figure 2.21. CD spectra during annealing at 56 °C, showing the thermal transition of 
PYY11 at pH 8.47 and 2 wt% from α-helix to β-sheet. 
 
SAXS data measured for the gels is shown in Figure 2.22b and was fitted to a long 
cylindrical shell model using SASfit, the fitting parameters being shown in Table 2.9. The 
form factor profiles and fitting parameters of PYY23 appear to be distinctly different to 
the other two lipidated peptides. The radius R is significantly larger than the others and 
the shell thickness DR is significantly lower. TEM images of all peptide gels (Figure 2.22c) 
show a network of entangled fibers, very similar to the cryo-TEM images of the samples 
in solution. An interesting observation is that PYY11 and PYY23 did not form a gel at pH 
2, which is informative in terms of understanding the mechanism of gelation, since they 
both form micelles at pH 2, whereas PYY17 forms fibers. This indicates that a fiber 
morphology could be crucial to gelation. 
Fiber X-ray diffraction (XRD) was performed to compliment the SAXS data, providing 
information on the local packing of the lipidated peptides, i.e. on secondary structure. 
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The obtained 2D patterns were isotropic, so the data were reduced to one-dimensional 
form. The resulting intensity profiles are shown in Figure 2.23. The results for PYY17 and 
23 show α-helical structures with sharp peaks corresponding to a d- spacing = 5.70 Å.34 
XRD results of PYY11 show the presence of β-sheet structures with sharp peaks 
corresponding to d-spacings = 10.01 and 4.65 Å.35 These are assigned as inter-sheet and 
inter-strand spacings in a ‘cross-β’ XRD pattern respectively. The apparent discrepancy 
between XRD showing α-helical structure and cryo-TEM/SAXS showing fibril structures 
requires further investigation to give explanation.   
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Figure 2.22. (a) CD spectra from gels of all three lipidated peptide at pH 7-8 and 20 oC. 
(b) SAXS intensity profiles and form factor fittings for gels of PYY11, PYY17, and PYY23 
at pH 7-8. All data was fitted to a long cylindrical shell form factor. (c) TEM images of 
the peptide hydrogels at pH 8. (i) PYY11, (ii) PYY17, (iii) PYY23. 
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Table 2.9. Form factor fitting parameters for PYY11, PYY17 and PYY23 gels at pH 7-8 and 
2 wt%, all fitted to a long cylindrical shell model. Key: BG = background. N = scaling 
factor. σ = Gaussian width. R = inner radius. DR =shell thickness. L = length of cylinder. 
ηcore= scattering contrast of core. ηshell= scattering contrast of shell. ηsolv= scattering 
contrast of solvent. 
 
 
Figure 2.23. Fibre XRD intensity profiles for PYY11, PYY17 and PYY23, measured from a 
hydrogel or from a dried stalk at varied pH, with main Bragg spacing indicated. 
Sample BG N / arb. 
units 
σ/ 
nm 
R / 
nm 
DR / 
nm 
L / 
nm 
ηcore ηshell ηsolv 
PYY11 
pH 8 
1.58x10-
3 
5.37x10-
9 
12.9 22.6 28.1 5000 -3.68 
x10-5 
-5.49 
x10-4 
2.00 
x10-4 
PYY17 
pH 8 
1.02 
x10-2 
1.01 
x10-5 
23.1 30.0 48.6 1000 2.70 
x10-4 
-6.91 
x10-5 
0.00 
PYY23 
pH 7 
8.26 
x10-6 
1.45 
x10-7 
14.8 55.2 6.55 5000 1.10x10-
3 
3.57 
x10-3 
5.90 
x10-4 
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Polarized optical microscopy was carried out on the peptide hydrogels using Congo red 
as a staining agent to show green birefringence in polarized light from the presence of 
amyloid fibrils.36-37 Congo red is an azo dye that has an orientated arrangement on 
amyloid fibrils by forming hydrogen bonds between amino and hydroxyl groups within 
the dye and on amyloid structures.38 When stained with Congo red in alkaline 
conditions, the fibrils appear red in unpolarized light, and green in polarized light. 
Microscopy images are shown in Figure 2.24 and yellow/green birefringence is observed 
for all three lipidated peptides, indicating the presence of amyloid fibrils. 
 
 
 
 
 
Figure 2.24. Polarized optical microscopy images of samples stained with Congo red to 
show birefringence in the presence of amyloid fibrils. a) PYY11 gel at pH 8, b) PYY17 gel 
at pH 8, c) PYY23 gel at pH 8. 
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2.2.3 Self-Assembly of PYY3-36 with Vitamin B12 
 
Although many studies on the use of PYY3-36 to reduce food intake have been very 
promising, the need for it to be injected creates problems with patient compliance and 
quality of life. Challenges associated with oral peptide therapeutics include: rapid renal 
clearance, proteolytic degradation in the stomach and intestine, and poor absorption 
due to their inability to cross the ileal epithelium.39  
The vitamin B12 dietary uptake pathway for use as a peptide delivery system has gained 
a significant amount of interest over the years.40  Vitamin B12 (B12), also known as 
cobalamin, is a water-soluble essential nutrient co-factor involved in the metabolism of 
every cell in animals, including humans. B12 is the largest B vitamin with a complex 
molecular structure. It consists of a nucleotide moiety and a planar porphyrin-like corrin 
ring, containing a central cobalt (III) atom Figure 2.25.40 Only certain bacteria synthesise 
B 12, and the main source for humans is found via dietary intake of meat and dairy 
products. 
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Figure 2.25. Chemical structure of vitamin B12. 
Humans have developed a highly efficient absorption and cellular uptake mechanism of 
B12 in the gastrointestinal tract, which can be adapted for peptide delivery as long as the 
recognition and affinity of the B12 binding proteins aren’t altered.39-40 B12 is efficiently 
absorbed and is protected in the GI tract by salivary haptocorrin (HC), a glycoprotein 
that has a high affinity for B12 under acidic conditions when the pH is less than 3.40 HC 
protects B12 from acid hydrolysis in the stomach, and upon binding forms a HC to B12 
complex, which then travels from the stomach to the duodenum. The pH is increased in 
the duodenum, causing a decrease in affinity of HC for B12. This allows HC to be digested 
by pancreatic enzymes, releasing B12. Following this, a second glycoprotein, intrinsic 
factor (IF) binds to B12, to facilitate the transport across the intestinal enterocyte via 
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receptor mediated endocytosis. Finally, B12 appears in the blood plasma up to 4 hours 
after ingestion.40 
A vital aspect when considering the use of B12 as a dietary uptake drug delivery system 
is receptor selectivity and activity. The interaction of B12 with the drug must not reduce 
the drug’s receptor selectivity, and the vitamin must still be recognised by the proteins 
involved in its uptake.40 In vitro studies on conjugated B12-PYY3-36 have been promising, 
showing a similar agonism for the Y2 receptor compared to native PYY3-36, implying that 
B12 does not seem to affect the biological activity of both the vitamin and the peptide.40 
Although investigations have been carried out on conjugated B12-PYY3-36 systems to look 
at biological activity, there seems to be limited research on non-covalent interactions. 
The following experiments look at the effect of B12 on the self-assembly of PYY3-36, to 
gain an insight into how they potentially interact with each other with relevance to 
possible drug delivery systems. 
CD studies of PYY3-36 with different molar ratios of B12 are shown in Figure 2.26a. There 
appears to be no significant impact on secondary structure using a 0.1:1 molar ratio of 
B12 to PYY3-36, with the spectrum exhibiting a predominant α-helix structure. Upon 
increasing the ratio of B12 to 2:1 B12:PYY3-36 however, there is a substantial loss of α-
helical structure, with reduced molar ellipticity, indicating that the addition of B12 above 
a concentration threshold disturbs secondary structure.  
Cryo-TEM images show that the increased molar ratio of B12 enhances aggregation, with 
a significantly larger number of nanotapes present as the molar ratio increases from 
0.1:1 to 2:1. SAXS was used to investigate this further. The data (Figure 2.26b) implies 
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that the different molar ratios have little impact on aggregation, since the scattering 
patterns mainly correspond to unimers, similar to PYY3-36 on its own. SAXS data was fit 
to a generalized Gaussian coil form factor to represent these unimers, and the fitting 
parameters are shown in Table 2.10. The discrepancy between cryo-TEM and SAXS, with 
cryo-TEM showing nanotapes which are not detected by SAXS can be attributed to the 
structures being dominated by unimers. This is due to SAXS measurements giving an 
overall average of the size and structure. SAXS parameters don’t appear to differ 
substantially when adding B12, with all ratios of B12 with PYY3-36 having similar structural 
parameters. As a result it can be concluded that the addition of vitamin B12 to PYY3-36 
does not impact aggregation significantly, and thus is a promising starting point to 
understanding the non-covalent interactions between them both. 
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Figure 2.26. a) CD spectra of PYY3-36 with vitamin B12 at 0.1:1, 1:1, and 2:1 molar ratios 
and 20 °C. b) SAXS intensity profiles and form factor fittings of PYY3-36 with vitamin B12 
at different molar ratios and native pH. All data was fitted to a generalized Gaussian coil 
form factor characteristic of unimers. c) TEM images of PYY3-36 with vitamin B12. (i) B12, 
(ii) 1:1 PY 3-36 to B12, (iii) 1:2 PYY3-36 to B12.  
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Table 2.10. SAXS form factor parameters of PYY3-36 (0.5 wt%) with vitamin B12 at native 
pH fit to a generalized Gaussian coil form factor model using SASfit. Key: BG = 
background. N= scaling factor. Rg = radius of gyration. ν = Flory exponent. I0= forward 
scattering. 
 
 
2.3 Conclusion 
 
Various physical characterisation techniques including but not limited to CD, 
microscopy, and X-ray techniques, have been employed to investigate the impact of 
lipidation on the self-assembly and gelation behaviour of the gut derived peptide 
hormone PYY3-36. 
Three lipidated derivatives of PYY3-36 were studied, with C16 alkyl chains covalently 
attached at positions 11, 17, and 23 to the peptide by substitution of γ-L-glutamoyl(Nα-
hexdecanoyl) lysine residues. Results show distinct differences between lipidated and 
Sample BG N / arb. units Rg / 
nm 
ν I0 
Vitamin B12 
 
4.0x10-4 9.83x10-2 5.292 0.410 6.7x10-2 
PYY3-36:B12 
(1:0.1 mol) 
7.0x10-4 0.455 20.31 0.226 7.5x10-2 
PYY3-36:B12 
(1:1 mol) 
7.0x10-4 0.447 20.08 0.310 7.3 x10-2 
PYY3-36:B12 
(1:2 mol) 
9.0x10-4 0.566 20.93 0.480 7.0x10-2 
PYY3-36:B12 
(1:3 mol) 
9.0x10-4 0.700 21.43 0.560 6.4x10-2 
PYY3-36 pH 6 
(native pH) 
2.1x10-4 1.00 22.12 0.295 8.4x10-2 
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unlipidated peptides, with the lipidated peptides having micelle and fiber morphology, 
and the unlipdated peptide being predominantly unimers with some nanotape 
structures. Furthermore, the lipidated peptides were more stable to pH and 
temperature change, and formed hydrogels under certain pH and temperature changes. 
The unlipidated peptide did not gelate under the conditions studied. 
Further experiments were carried out using vitamin B12 (B12), to look at the non-covalent 
interactions between B12 and PYY3-36. Results show that the addition of B12 has an impact 
on self-assembly. As the ratio of B12 was increased, the α-helical conformation 
decreased shown by CD. SAXS showed predominantly unimers throughout the 
concentration range of B12 used, and cryo-TEM suggested that B12 enhanced fibril 
aggregation as the concentration was increased. Further experiments are required to 
understand the behaviour in more detail but these experiments are a promising starting 
point. 
 
 2.4 Materials and Methods 
 
Human PYY3-36 acetate salt was synthesised by Bachem, Switzerland. The molecular 
mass by MALDI-MS was measured by the supplier using a Shimadzu Biotech Axima-CFR 
instrument, and found to be 4049.61 g mol-1 (expected: 4047.07 g mol-1). The molecular 
mass was checked in our labs by ESI-MS using a Thermo Scientific LTQ- Orbitrap XL 
instrument, and found to be 4049.07 g mol-1. The purity was 96.9% determined by HPLC. 
PYY11 acetate salt was custom synthesised by Bachem, Switzerland. The molecular mass 
by MALDI-MS was measured by the supplier using a Shimadzu Biotech Axima-CFR 
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instrument, and found to be 4458.19 g mol-1 (expected: 4454.37 g mol-1).The molecular 
mass was checked in our labs by ESI-MS using a Thermo Scientific LTQ- Orbitrap XL 
instrument, and found to be 4458.41 g mol-1. The purity was 95.4 % as determined by 
HPLC. 
PYY17 acetate salt was custom synthesised by Bachem, Switzerland. The molecular mass 
by MALDI-MS was measured by the supplier using a Shimadzu Biotech Axima-CFR 
instrument, and found to be 4389.13 g mol-1 (expected: 4387.32 g mol-1). The molecular 
mass was checked in our labs by ESI-MS using a Thermo Scientific LTQ- Orbitrap XL 
instrument, and found to be 4389.32 g mol-1. The purity was 97.8 % as determined by 
HPLC. 
PYY23 acetate salt was custom synthesised by Bachem, Switzerland. The molecular mass 
by MALDI-MS was measured by the supplier using a Shimadzu Biotech Axima-CFR 
instrument, and found to be 4389.27 g mol-1 (expected: 4387.32 g mol-1). The molecular 
mass was checked in our labs by ESI-MS using a Thermo Scientific LTQ- Orbitrap XL 
instrument, and found to be 4389.33 g mol-1. The purity was 98.3% as determined by 
HPLC. 
2.4.1 Fluorescence Spectroscopy 
 
Fluorescence spectra were recorded with a Varian Cary Eclipse fluorescence 
spectrometer (Varian IEEE-488, Australia) with samples in 4 mm inner diameter quartz 
cuvettes. Pyrene assays were performed using 1.3 x10-3to 0.13 wt% peptide solutions, 
in 2.167 x10-5 wt% pyrene solution. The samples were excited at a wavelength λex = 339 
nm, and the fluorescence emission was measured for λ = 360−500 nm. Thioflavin T (ThT) 
assays were performed using 1.3 x10-3 to 0.13 wt% peptide solutions, in 5.0 x 10-3 wt% 
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ThT solution. The samples were excited at a wavelength λex = 440 nm, and the 
fluorescence emission was measured for λ = 460−600 nm. 
2.4.2 Circular Dichroism (CD) 
 
CD spectra were recorded using a Chirascan spectropolarimeter (Applied Photophysics, 
UK). Spectra are presented with absorbance A < 2 at any measured point with a 0.5 nm 
step, 1 nm bandwidth, 1 s collection time per step, and 3 repeats. The CD signal from 
the background (water) was subtracted from the CD signal of the sample solution. 
Ellipticity is reported as the mean residue ellipticity ([θ], in deg cm2/dmol) and 
calculated as: 
[θ] = [θ]obs MRW/10cl  
Where [θ]obs is the ellipticity measured in millidegrees, MRW is the mean residue 
molecular weight of the peptide (molecular weight divided by the number of amino acid 
residues), c is the concentration of the sample in mg/mL, and l is the optical path length 
of the cell in centimeters. 
Samples were measured using quartz plaques (0.2 mm spacing for solutions and 0.01 
mm for gels) with 0.5 wt% solution concentrations with a pH range from 2-8. Gel 
concentrations measured ranged from 1.6-2.4 wt%. CD spectra were measured using a 
temperature range of 20-70 °C and a 5 °C step. The sample was equilibrated at each 
temperature for 2 minutes before measurements were recorded. 
2.4.3 Cryogenic Transmission Electron Microscopy (Cryo-TEM) 
 
Imaging was carried out in Finland by Jani Seitsonen, and Janne Ruokolainen, using a 
field emission cryo-electron microscope (JEOL JEM-3200FSC) operating at 200 kV. 
97 
 
Images were taken using bright-field mode and zero loss energy filtering (omega type) 
with a slit width of 20 eV. Micrographs were recorded using a CCD camera (Gatan 
Ultrascan 4000, USA). The specimen temperature was maintained at -187 °C during the 
imaging. Vitrified specimens were prepared using an automated FEI Vitrobot device 
using Quantifoil 3.5/1 holey carbon copper grids, with a 3.5 μm hole sizes. Grids were 
cleaned using a Gatan Solarus 9500 plasma cleaner just prior to use and then transferred 
into the environmental chamber of a FEI Vitrobot at room temperature and 100% 
humidity. Following this, 3 μL of sample solution at 0.5 wt % concentration was applied 
on the grid, blotted once for 1 s, and then vitrified in a 1:1 mixture of liquid ethane and 
propane at −180 °C. Grids with vitrified sample solutions were maintained in a liquid 
nitrogen atmosphere and then cryo-transferred into the microscope. 
2.4.4 Transmission electron microscopy (TEM) 
 
Imaging was performed using a 2100 plus TEM instrument. A thin film of peptide gel 
was added to the surface of a carbon film coated TEM grid and stained with 1 wt% uranyl 
acetate solution for 1 minute, followed by washing with distilled water by applying 
enough water to cover the grid and leaving it for 1 minute. The grids were then taken 
and placed in the TEM Instrument and images were taken, using a 4.0 megapixel CMOS 
camera, at various magnifications. 
2.4.5 Polarized Optical Microscopy (POM) 
 
Images were obtained with an Olympus BX41 polarized microscope by placing the 
sample between crossed polarizers. Approximately 20 µL of Congo red solution (450 
µM) was added to gel samples and left for an hour to allow the Congo red solution to 
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absorb into the gels. The resulting mixtures were placed between a glass slide and a 
coverslip. Images were collected using an Olympus SP-350 digital camera. 
2.4.6 Small-Angle X-ray Scattering (SAXS) 
 
Solution SAXS experiments were performed on the bioSAXS beamline BM29 at the ESRF, 
Grenoble, France, and also on the bioSAXS beamline B21 at Diamond, Harwell, UK. 
Solutions containing 0.5 wt% of peptide in water were loaded into PCR tubes in an 
automated sample changer. At the ESRF, SAXS data were collected using a Pilatus 1 M 
detector. The sample−detector distance was 2.84 m. The X-ray wavelength was 0.99 Å. 
At Diamond, SAXS data was collected using a 2 M detector and at a fixed camera length 
of 3.9 m with a wavelength λ = 1 Å. The wavenumber q = 4π sin θ/ λ scale was calibrated 
using silver behenate, where λ is the x-ray wavelength and 2θ is the scattering angle. 
SAXS on hydrogels was performed at Diamond on beamlines I22 and B21. On I22, 
Samples were placed in DSC pans modified with mica or Teflon windows to enable 
transmission of the X-ray beam. The sample-to-SAXS detector distance was 7.483 m. A 
Pilatus P3-2M detector was used to acquire the 2D SAXS scattering patterns. SAXS data 
collected for samples with Teflon windows was corrected for the Teflon background 
scattering. Diffraction from silver behenate was used to calibrate the wavevector scale 
of the scattering curve. Data processing was performed using software DAWN (Data 
Analysis Software group, Diamond Light Source Ltd.). On beamline B21 at Diamond, 
samples were placed in custom made gel holder cells with Kapton (polyimide) windows. 
SAXS data was collected using a 2 M detector and at a fixed camera length of 3.9 m with 
a wavelength λ = 1 Å. 
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2.4.7 Fiber X-ray Diffraction (XRD) 
 
XRD of gels (1.6-2.4 wt%) was performed on dried peptide stalks prepared by creating a 
fibre of peptide between the ends of wax coated capillaries. After separation of the 
capillaries after drying, a stalk was left on the end of one of the capillaries. Stalks were 
vertically mounted onto the goniometer of an Oxford Diffraction Gemini Ultra 
instrument, equipped with a Sapphire CCD detector. The sample to detector distance 
was 44 mm. The X-ray wavelength was λ = 1.54 Å. The wavenumber scale (q = 4π sin θ/λ 
where 2θ is the scattering angle) was geometrically calculated. 
2.4.8 Zeta Potential (ζ) 
 
ζ potentials were measured using a Zetasizer Nano ZS from Malvern Instruments. A 1 
mL aliquot of sample was placed inside a disposable folded capillary cell. The sample 
was left to equilibrate for 120 s before measuring the ζ potential, using an applied 
voltage of 50.0 V. The results presented are the average over three measurements. 
2.4.9 pH titration measurement 
 
Titrations were carried out using 2 wt% peptide solutions in water (3 mg in 150 µL). 
Sodium hydroxide (0.25 M) was added to the peptide solutions until pH 10 was reached. 
Titrations were performed by adding diluted HCl (0.022 M) dropwise, and measuring 
the pH using a pH meter until the pH had dropped to pH 2. Water was also titrated in 
the same way as a control experiment. 
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2.4.10 Nanodrop Concentration Determination 
 
For gels, concentrations were measured using a Thermo Scientific NanoDrop 1000 
spectrophotometer, and ND-1000 version 3.7 software. 2 μL of each sample was 
pipetted onto a cleaned measurement pedestal. The absorbance at 280 nm was 
recorded. A molar absorbance coefficient was calculated using the following equation,ε 
= (nW × 5500) + (nY × 1490) + (nC × 125). At 280 nm, this is the weighted sum of the 280 
nm molar absorption coefficients of tryptophan (W), tyrosine (Y) and cysteine (C) amino 
acids. Given there are four tyrosine residues in each of the lipidated peptides this 
equation produces a molar absorbance coefficient of 5960 L mol-1 cm-1. This absorbance 
and molar absorbance coefficient were then used to calculate the molarity using the 
Beer-Lambert equation. From the molarity the weight of peptide present was found and 
subsequently converted to a weight percent, using known volumes and molecular 
weights. 
 
2.4.11 PYY11 Hydrogel Formation 
 
Gels of PYY11 were prepared by making up 1-2 wt% peptide solutions in ultrapure water 
and changing the pH accordingly using 1 M HCl or 1 M NaOH. The solutions were heated 
to 60 °C for approximately 2 hours and then left to stand for a couple of hours to a 
couple of days for the gelation to occur. The concentration of gels was determined by 
Nanodrop experiments and ranged from 1.6-2.4 wt%. The pH range studied was pH 2-
8. 
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Chapter 3 - The Self-Assembly of Lipopeptides Containing Short 
Peptide Fragments Derived from the Gastrointestinal Hormone 
PYY3-36: From Micelles to Amyloid Fibrils 
3.1 Introduction 
The self-assembly of three lipidated peptide fragments of the gastrointestinal peptide 
hormone PYY3-36 is studied in this chapter, and compared to the native fragments.  
Previous studies on various truncated versions of PYY have examined the Y2 receptor 
affinity and biological function, specifically at the C-terminus.1 The self-assembly of 
truncated PYY peptides however has not been studied.  
Here, we investigate the effect of pH, temperature, concentration, and lipidation on the 
self-assembly and conformation of three truncated fragments of PYY3-36. The peptides 
studied consist of the first six and eight amino acid residues of the whole peptide 
sequence, with a palmitoyl alkyl chain covalently attached either at the N-terminus 
(IKPEAP and IKPEAPGE), or the C-terminus (PAEPKI) (Figure 3.1). Cytocompatibilty 
studies using MTT assays are also investigated to test cytotoxicity. The palmitoyl chain 
that is typically attached to the peptide is able to bind to serum albumin, causing steric 
hindrance, helping to delay proteolytic attack and renal clearance.2, 3-5   
Studies have shown that PYY3-36 has a partially α-helical secondary structure.6 The short 
peptide fragments studied here are not within the α-helical part of the whole sequence, 
and they also contain proline residues which are structure breaking residues that 
disfavour α-helix confirmations.7 This occurs due to the disruption of hydrogen bonding 
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caused by the amide bond lacking the proton necessary for hydrogen bond stabilisation. 
Lipidation using palmitoyl (C16, hexadecyl) chains is favourable, as it allows the molecule 
to fuse with the cell membrane and potentially act as a transducing molecule in vivo.8  
 
 
 
 
 
 
 
 
 
 
 
 
  
c) 
Figure 3.1. Chemical structures of a) C16IKPEAP, b) C16IKPEAPGE, and c) PAEPKI-NH-
C16H33. 
a) 
b) 
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3.2 Results and Discussion 
 
3.2.1 C16IKPEAP and C16IKPEAPGE 
 
Fluorescence measurements using 8-anilinonaphthalene-1-sulfonic acid (ANS), and 
pyrene as fluorescent probes, were carried out to determine the critical micelle 
concentrations (cmc) of C16IKPEAP and C16IKPEAPGE. ANS interacts with hydrophobic 
binding sites to cause an increase in fluorescence and a blue shift of the λmax.9 Pyrene is 
also sensitive to the hydrophobic environment, and in the presence of micelles and 
other macromolecular systems, it becomes encapsulated in the interior hydrophobic 
regions of the aggregates.10 Figure 3.2 shows results of ANS fluorescence 
measurements, and calculated critical micelle concentration (cmc) values were 0.0056 
wt% and 0.0029 wt% for C16IKPEAP and C16IKPEAPGE respectively at their native pH in 
water. Results for the non-lipidated IKPEAP and IKPEAPGE did not show a distinct break 
in the intensity of fluorescence and it appears these peptides do not aggregate. 
Fluorescence experiments using pyrene were also carried out as a function of pH to 
investigate the effect of pH on aggregation concentration. Results indicate an increase 
in cmc with increased pH for both peptides (Figure 3.3 and Table 3.1). Interestingly there 
was no cmc observed for C16IKPEAPGE at pH 12. It’s not fully understood why this is, but 
it could be due to the negative charge caused by the additional glutamic acid residue 
affecting aggregation of the larger peptide at higher pH.  
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Figure 3.2. Concentration dependence of ANS Imax fluorescence to show the critical 
micelle concentration (cmc) of the lipidated peptides at their native pH in water. The 
intersection of the lines indicates the cac. 
 
Figure 3.3. Concentration dependence of pyrene fluorescence I1 (373 nm), at 20 o C, to 
show pH dependence on the cmc of (a) C16IKPEAP in the pH range 4-12 and (b) 
C16IKPEAPGE in the pH range 2-8. The intersection of the lines defines the cmc.  
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Table 3.1. Tabulated critical aggregation concentration values of C16IKPEAP and 
C16IKPEAPGE in the pH range 2-12 and at 20 o C. 
 
 
 
 
 
Further fluorescence experiments were performed to investigate the interaction of the 
two lipidated peptide fragments with bovine serum albumin (BSA). Peptide 
concentrations well above the cmc were used, with BSA concentrations of 0.00375 wt%. 
Serum albumin accounts for around 60% of the total serum content in humans, making 
it the most abundant plasma protein for use in transportation of a wide variety of 
substrates such as hormones and metabolites.11 The experiment carried out here was 
just a simple fluorescence experiment, to determine whether the peptide bound to BSA. 
Interestingly the peptide appeared to have auto-fluorescence with an emission 
wavelength of around 315 nm in the absence of BSA, which was surprising since the 
peptide does not contain any aromatic residues. The auto-fluorescence must therefore 
be due to the proline residues, which have been shown to auto-fluoresce with emission 
wavelengths ranging from 298-446 nm depending on the excitation wavelength.12 
Results show that there is a significant increase in intensity of both lipidated peptides in 
the presence of BSA, with a slight red shift to show a decrease in hydrophobicity,13 
 C16IKPEAP C16IKPEAPGE 
Native pH (wt %) 0.0049 0.0044 
pH 4 (wt %) 0.0040 0.0030 
pH 8 (wt%) 
 
pH 12 
0.0051 
 
0.011 
0.017 
 
- 
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suggesting that the peptide has successfully bound to it (Figure 3.4). Further 
experiments are required to understand the binding interactions between the peptides 
and BSA however. These could include calculating the binding contant, K, and also using 
different concentrations of peptide and BSA.  
 
 
 
 
 
 
 
 
 
Circular dichroism (CD) was used to determine secondary structure at concentrations 
above the cmc for the lipidated peptides. The same concentration of non-lipidated 
peptides were also used for comparison. Spectra of lipidated and unlipidated peptides 
were compared to determine what effect, if any, that the lipidation had on the 
secondary structure of the peptides. Spectra at the peptides native pH and 20 o C showed 
a disordered conformation for both C16IKPEAP, and C16IKPEAPGE, and a polyproline II 
helix for IKPEAP and IKPEAPGE, with positive molar ellipticity values near 220 nm 14-15 
Figure 3.4. Fluorescence emission spectra to show bovine serum 
albumin binding of C16IKPEAP, and C16IKPEAPGE at 20 o C. 
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(Figure 3.5). CD spectra at other pH values studied (pH 4-12) showed a disordered 
structure with minimum at around 195 nm at 20 o C (Figure 3.6). 
Temperature ramp CD experiments to study thermal stability from 20-70 o C display 
similar results, shown in Figures 3.7-3.8. Lipidation enhances thermal stability at pH 4 
since the lipidated peptides are much more thermally reversible when compared to the 
peptides themselves, shown by molar ellipticity values being more negative. Lipopeptide 
C16IKPEAP at native pH (pH 6.28), and pH 8 appears to have very little secondary 
structure. This could be attributed to the measured pH values being close to the  
calculated isoelectric point which was found to be pH 6.86 for IKPEAP, whereas for 
IKPEAPGE it was pH 4.15, using Innovagen software.16 The additional two residues; 
glutamic acid and glycine in the latter peptide lead to a substantial increase in peptide 
chirality, pointing to the important role of the charged terminal glutamic acid residue, 
since glycine is achiral. At pH 4 the molar ellipticity values are all fairly similar for all 
peptides, with the lipidated derivatives having a slight red shift. Results in the pH range 
8-12 indicate that lipidation enhances the secondary structure of the larger peptide 
fragment, with molar ellipticity results 2 x 104 deg cm2 dmol-1 more negative for the 
C16IKPEAPGE fragment compared to IKPEAPGE.  
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Figure 3.5. CD spectra comparing lipidated and unlipidated peptides at native pH 
and 20 oC. 
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Figure 3.6. CD spectra comparing lipidated and unlipidated peptides at 20 o C. 
a) pH 4, b) pH 8, c) pH 12. 
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Figure 3.7. CD spectra showing thermal stability of C16IKPEAP and IKPEAP from 
20-70 o C. a) native pH of the peptide (pH 6.28 for C16IKPEAP and pH 2.46 for  
IKPEAP), b) pH 4, c) pH 8, d) pH 12. 
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Cryogenic transmission electron microscopy (cryo-TEM) images of C16IKPEAP and 
C16IKPEAPGE showed the presence of micelles with a radius less than 5 nm (Figure 3.9). 
In contrast, cryo-TEM images of IKPEAP and IKPEAPGE showed no self-assembled 
structures at the same concentration (1 wt%). This is in agreement with the fluorescence 
probe measurements which revealed no cmc.  
Dynamic light scattering (DLS) was used to provide an independent measure of the 
micelle size. The number weighted radius distributions at θ = 90° of the lipidated 
peptides are shown in Figure 3.10. The number weighted radius values were 1.90 nm 
Figure 3.8. CD spectra showing thermal stability of C16IKPEAPGE and IKPEAPGE 
from 20-70 o C. a) native pH of the peptide (pH 1.60 for C16IKPEAPGE and pH 
2.27 for  IKPEAPGE), b) pH 4, c) pH 8, d) pH 12. 
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and 3.07 nm for C16IKPEAP and C16IKPEAPGE respectively which agreed with the cryo-
TEM images that show the micelles to be less than 5 nm in radius. 
  
Figure 3.10. DLS intensity distributions showing the number weighted radius of 
C16IKPEAP and C16IKPEAPGE at native pH and 0.1 wt% 
Figure 3.9. Cryo-TEM images  obtained by J. Seitsonen  and  J. Ruokolainen, 
Finland, of: (i) C16IKPEAP and (ii) C16IKPEAPGE at native pH and 1 wt% 
showing micelles. 
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Small-angle X-ray scattering (SAXS) was used to further investigate the shape and size of 
the self-assembled peptide nanostructures in solution. The intensity profiles with model 
form factor fits of the lipidated peptide fragments are shown in Figure 3.11, and the 
fitted parameters are shown in Tables 3.2-3.3. The profiles of the lipidated fragments 
are consistent with the cryo-TEM images that showed spherical micelle structures, and 
the data can be fitted to a spherical shell form factor. The unlipidated fragments showed 
completely different shaped intensity profiles, and again were consistent with cryo-TEM 
images where there was no observable self-assembled structure. The SAXS data was 
fitted to a generalized Gaussian coil form factor to represent monomers in solution 
(Figure 3.12), and the fitted parameters are shown in Tables 3.4-3.5. 
Ths SAXS data of the lipidated peptide fragments reveals differences in the outer radius 
of the micelles as a function of pH. Increasing the pH from 2 to 8 significantly decreases 
the radius for both peptide systems. This could be related to the loss of charge on the 
lysine residue at pH 8, causing an increase in net negative charge in the micelle, thus 
reducing the size. When comparing both lipidated peptides over pH 2-8, there are no 
obvious differences in the size of aggregates, suggesting that the length of the peptide 
does not affect the self-assembly behaviour, and that pH is the main contributing factor.  
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Figure 3.11. SAXS intensity profiles and form factor fits in the pH range 2-12. a) 0.134 wt% 
C16IKPEAP, b) 0.162 wt% C16IKPEAPGE. Data was fitted to a spherical shell form factor. 
Figure 3.12. SAXS intensity profiles and form factor fits in the pH range 2-12. a)  0.13 
wt% IKPEAP, b) 0.16 wt% IKPEAPGE. Peptides were fitted to a generalized Gaussian 
coil form factor. 
118 
 
 
 
Table 3.1. SAXS form factor parameters of C16IKPEAP (0.134 wt%) at pH 2-8 fit to a 
spherical shell form factor model using SASfit.17 Key: BG = background, N= scaling factor, 
σ = polydispersity in outer radius (Gaussian width), R1= outer radius, R2 = inner radius,  μ 
= scattering contrast of the shell, η = scattering contrast of inner core. 
Sample BG N / arb. 
units 
σ/ nm R1 / nm R2 / nm µ η 
C16IKPEAP 
pH 2 
0.310 0.604 0.486 3.26 1.91 -1.36 5.5x10-2 
C16IKPEAP 
pH 4 
0.525 0.602 0.713 3.24 1.76 -1.87 4.75x10-
2 
C16IKPEAP 
pH 6 
(native 
pH) 
0.200 0.554 0.535 3.24 1.60 -1.87 4.75x10-
2 
C16IKPEAP 
pH 8 
0.776 1.04 0.926 2.67 1.66 -1.69 5.12x10-
2 
C16IKPEAP 
pH 12 
1.41x10-
3 
1.61x10-
8 
3.78 31.82 16.09 -1.64 2.36x10-
2 
Table 3.3. SAXS form factor parameters of C16IKPEAPGE (0.162 wt%) at pH 2-8 fit to a 
spherical shell form factor model using SASfit.17 Key as for Table 3.2. 
Sample BG N / arb. 
units 
σ/ nm R1 / nm R2 / nm µ η 
C16IKPEAPGE 
pH 2 (native 
pH) 
0.266 1.01 0.535 3.18 1.88 -1.03 5.33x10-2 
C16IKPEAPGE 
pH 4 
0.281 1.00 0.566 3.39 1.72 -1.44 4.53x10-2 
C16IKPEAPGE 
pH 8 
0.500 1.17 0.861 2.71 1.51 -1.39 4.73x10-2 
C16IKPEAPGE 
pH 12 
1.6x10-3 1.31x10-8 4.59 32.16 15.15 -1.36 2.59x10-2 
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Table 3.4. SAXS form factor parameters of IKPEAP at pH 2-8 fit to a generalized Gaussian 
coil form factor model18 for which 𝑹𝒈
𝟐 = 𝒂𝒏𝟐𝒗/(𝟐ν + 𝟏)(𝟐ν + 𝟐) where a is the 
segment length, n is the chain length and ν is the Flory exponent) form factor model 
using SASfit.17 Key: BG = background, N= scaling factor, Rg = radius of gyration, I0 = 
forward scattering. 
Sample BG N / arb. 
units 
Rg/ 
nm 
ν I0 
IKPEAP 
pH 2 (native 
pH) 
 
0.195 
 
1.64 
 
1.82 
 
0.818 
 
0.902 
IKPEAP 
pH 4 
0.605 1.33 1.02± 
0.02 
0.925± 
0.03 
1.12 
IKPEAP 
pH 8 
0.500 1.16 1.01± 
0.02 
0.912± 
0.03 
1.08 
IKPEAP 
pH 12 
1.9x10-3 8.65x10-3 7.75 0.248 0.276 
Table 3.5. SAXS form factor parameters of IKPEAPGE at pH 2-8 fit to a 
generalized Gaussian coil form factor model using SASfit.17 Parameters as 
for Table 3.4. 
Sample BG N / arb. 
units 
Rg/ 
nm 
ν I0 
IKPEAPGE 
pH 2 (native 
pH) 
8.3x10-2 2.19 1.70± 
0.015 
0.966 1.01± 
0.015 
IKPEAPGE 
pH 4 
0.161 1.63 1.15 0.90 1.33 
IKPEAPGE 
pH 8 
0.275 1.57 1.10 0.903 1.21 
IKPEAPGE 
pH 12 
1.6x10-3 1.2x10-2 7.04 0.189 0.349 
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We unexpectedly noticed that drying samples for various measurements led to a 
profound difference in peptide conformation and self-assembled nanostructure. CD 
spectra measured on dried films show a β-sheet secondary structure for both peptides 
(Figure 3.13a). TEM images revealed the presence of short fibres with lengths of 400-
500 nm (Figure 3.13b), showing that drying leads to disruption of the micelle structures 
present in solution, as revealed by cryo-TEM (Figure 3.9).  
Fiber X-ray diffraction (XRD) was performed to directly examine secondary structure. 
The lipidated peptides have a β-sheet secondary structure with d-spacings of 4.68, 9.36, 
and 9.64 Å (Figure 3.13c). Results for the unlipidated fragments show a lack of secondary 
structure with d-spacing of 4.52 Å, representative of lipid chain packing (Figure 3.14). 
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Figure 3.13. (a) CD spectra obtained from dried films. (b) TEM images of dried (i) 
C16IKPEAP and (ii) C16IKPEAPGE at native pH showing fibres and micelles.(c) Fibre X-ray 
diffraction intensity profile of C16IKPEAP, and C16IKPEAPGE at native pH. (d) SAXS 
intensity profiles of dried C16IKPEAP, and C16IKPEAPGE at native pH. Arrows shown 
highlight Bragg peaks. 
 
Figure 3.14. Fibre X-ray diffraction intensity profile of 
IKPEAP, and IKPEAPGE at native pH, showing a Bragg 
spacing of 4.52 Å. 
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3.2.2 PAEPKI-NH-C16H33 
 
Further studies to look at the impact of lipidation at the C-terminus, by attachment of a 
palmitoyl amide group were investigated. This was to understand the effect of the 
lipidation site on self-assembly, but also to allow for the proline amino acid to be ‘free’, 
in the hope it acts as a catalyst in aldol reactions.  Organocatalysts involving L-proline 
residues have been reported successfully as asymmetric catalysts for a wide range of 
synthetic reactions.19-20 Of particular interest is L-proline derived organocatalysts 
containing long hydrophobic chains, as they have been found to perform aldol reactions 
in reaction mixtures containing both water and organic solvents.21 Studies carried out 
on a lipidated peptide with a C16 palmitoyl chain attached at the C-terminus and a proline 
based head group (PRW-C16), was found to be an excellent catalyst for aldol reactions 
performed in water, with very good stereoselectivity and conversion rates.22 The 
lipidated peptide self-assembled into spherical micelles above a cmc, and the self-
assembled structures were the driving force of the catalysis, since poor results were 
obtained in the absence of lipidated assembles. Other studies by Miravet et al. reported 
examples of aldol reactions catalyzed by L-proline-derived amphiphilic peptide gels 
based on self-assembled fibers.23-24 
Aldol reactions combine two carbonyl compounds to form a new C-C bond, to produce 
a compound containing a β-hydroxy carbonyl group,25-26 largely found in living 
organisms with exceptional pharmacological activities. Since the 1970s, L-proline has 
proven to be a very efficient organocatalyst for aldol reactions.27 Many of the aldol 
reactions involving L-proline are carried out in organic solvents such as DMSO and 
chloroform which are harmful and environmentally unfavourable.22 As a result, there 
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are current challenges to overcome this by replacing the solvents with more 
environmentally friendly ones, water being the most attractive one. The use of water is 
also attractive for promoting self-assembly by hydrophobic interactions and hydrogen 
bonding. 
The peptide studied in this chapter is a truncated peptide fragment of PYY3-36, with a 
palmitoyl chain (hexadecyl, C16) attached to the peptide head group at the C-terminus. 
The peptide sequence is PAEPKI (the same sequence studied earlier in the chapter, but 
with the C16 chain attached at the C-terminus) (Figure 3.1c). Since C16IKPEAP (N-terminal 
lipidation) was found to self-assemble into micelles and fibers depending on 
concentration, we first investigate the effect of the lipidation point (C-terminus versus 
N-terminus) on conformation and self-assembly. In collaboration with the group of W. 
Alves (UFABC, Brazil), the peptide’s ability to serve as a catalyst for a model Aldol 
reaction was then studied, this being facilitated by the free N-terminal proline. 
Firstly, the presence of a critical aggregation concentration (cac) to determine 
aggregation was carried out using ANS and pyrene as the fluorescent probes. Plots of 
Intensity as a function of concentration show distinct breaks at 1.73 x 10-3, and 2.5 x 10-
3 wt% at native pH (pH 3) and pH 8 respectively, suggesting that hydrophobicity 
decreases as the pH is increased (Figure 3.15). This is the same trend as what was seen 
for C16IKPEAP, however the cac values of PAEPKI-NH-C16H33 are considerably lower than 
those found for C16IKPEAP, implying that the ‘free’ proline residue increases the 
hydrophobicity of the peptide. ANS was unsuccessful when used at higher pH. It is not 
fully understood why, but it is thought to be due to the chemical structure of ANS 
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containing polar groups that become ionized with pH change, which reduces the ability 
of the peptide to bind to it as a result of charge repulsion. 
 
 
  
Figure 3.15. a) Concentration dependence of ANS Imax fluorescence to show the 
critical aggregation concentration (cac) of PAEPKI-NH-C16H33 at its native pH in 
ultrapure water (pH 3). The intersection of the lines indicates the cac. b) 
Concentration dependence of pyrene fluorescence I1 (373 nm) of PAEPKI-NH-
C16H33 at pH 8 to show pH dependence on the cac. c) Fluorescence emission 
spectra using ANS with PAEPKI-NH-C16H33 at native pH in ultrapure water. D) 
Fluorescence emission spectra using pyrene with PAEPKI-NH-C16H33 at pH 8. 
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CD experiments at native pH and pH 8 at 20 o C show a partial alpha helical content with 
two minima around 208 nm and 222 nm (Figure 3.16), that quickly transitions to a 
disordered structure with a minimum near 195 nm when the temperature is increased 
to 40 o C and above. This is contrast to C16IKPEAP where a disordered structure is present 
throughout the temperature range studied. The results show that the peptide is partially 
thermally reversible after the first heating cycle, with molar ellipticity values becoming 
more negative when the temperature is cooled from 80 oC to 20 oC. This does not occur 
in the second cycle however, indicating peptide degradation after repeated heating. In 
comparison to lipidation at the N-terminus, this is a very interesting result because the 
N-terminal truncated peptide C16IKPEAP is fully reversible after one heat cycle (Figure 
3.7-3.8). 
 
 
 
 
Figure 3.16. Temperature ramp CD of PAEPKI-NH-C16H33 with two temperature cycles from 
20-80 o C. a) native pH, b) pH 8. 
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Cryo-TEM images show the presence of long inter-tangling fibers with lengths exceeding 
500 nm (Figure 3.17a). Although cryo-TEM suggested a fiber morphology, the SAXS 
intensity profiles are more consistent with a micelle morphology, implying that the 
majority of the aggregates are micelles. Data was fitted to a spherical shell form factor 
fitting, and the fitted parameters are shown in Table 3.5. XRD was used to directly 
examine secondary structure, and results show a β-sheet structure with d-spacings of 
4.67 Å (Figure 3.17c). 
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Figure 3.17. a) Cryo-TEM of C16PAEPKI-NH-C16H33 at native pH (pH 3) showing a 
fiber morphology. b) SAXS intensity profiles of C16PAEPKI-NH-C16H33 at native pH, 
and pH 8. Data was fitted to a spherical shell form factor to represent micelles. c) 
XRD of C16PAEPKI-C16H33 with d-spacings of 4.67 Å representative of β-sheet 
secondary structure. 
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3.2.3 Cytocompatibility studies using an MTT assay 
 
Cytocompatibility studies of PAEPKI-NH-C16H33 were performed using an MTT ((3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay on human colorectal 
tumour cells (HCT-116 cell line), to determine cell viability (Figure 3.18-3.19). HCT-116 
was chosen because it is a gastrointestinal cell line, and therefore of relevance to the 
peptide since it is released from the gut. MTT is a yellow tetrazole that becomes reduced 
by NADPH dependant oxidoreductase enzymes in living cells, to produce purple 
formazan crystals.28-29 The crystals are then used to measure the number of viable cells 
using fluorescence spectroscopy.  
Table 3.5. SAXS form factor parameters of PAEPKI-NH-C16H33  at native 
pH (pH 3) and pH 8 fit to a spherical shell  form factor model using 
SASfit. Key: BG = background, N= scaling factor, σ = polydispersity in 
outer radius (Gaussian width), R1= outer radius, R2 = inner radius, μ = 
scattering contrast of the shell, η = scattering contrast of inner core. 
 
 
 
Sample 
 
1 wt% 
PAEPKI-NH-
C16H33 
pH 3  (native pH) 
 
1 wt% 
PAEPKI-NH-C16H33 
pH 8 
BG 1.8x10-4 1.0x10-3 
N / arb. units 2.73x10-4 1.12x10-7 
σ/ nm 0.42 5.36 
R1 / nm 3.29 34.52 
R2 / nm 1.75 20.06 
µ -1.44 -0.04 
η 0.084 0.0047 
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The IC50 (half maximal inhibitory concentration) was found to be 2 x 10-3 wt% , which is 
very close to the cmc (Figure 3.18). Above this concentration, there is a significant 
decrease in cell proliferation, with only around 20 % of cells still viable. This suggests 
that the peptide becomes cytotoxic to the cells when it starts to aggregate. Further 
studies to look at a wider concentration range close to the cytotoxic concentration, 
would be useful in determining this is more detail. Furthermore it would be interesting 
to carry out work on a normal GI cell line to compare cytotoxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18. Cytocompatibility studies on PAEPKI-NH-C16H33 using an 
MTT assay on human colorectal tumour cells (HCT-116), using 
peptide concentrations above and below the cmc.  
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.4 The use of PAEPKI-NH-C16H33 as an organocatalyst  
 
The use of L-proline derived organocatalysts containing long hydrophobic chains for use 
in aldol reactions has shown considerable success.21, 30-31 The high demand for more 
environmentally friendly processes makes L-proline derived organocatalysts somewhat 
favourable, since they have the ability to carry out reactions in solvent systems 
containing water as mentioned earlier in the chapter. 
An investigation to understand the ability of PAEPKI-NH-C16H33 containing a “free” 
proline residue to act as a catalyst in aldol reactions between p-nitrobenzaldehyde and 
cyclohexanone were carried out by Juliane Pelin, Federal University of ABC, Brazil 
(scheme 3.1).  
Figure 3.19. Cell viability as a function of peptide concentration of 
PAEPKI-NH-C16H33 on HCT-116 human colorectal tumour cells. The 
dashed red line is the sigmoidal fit of the data. 
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Experiments were carried out at room temperature with different excesses of water in 
relation to cyclohexanone. Results show that the peptide successfully acted as an 
organocatalyst in the reaction, but unfortunately as the excess of water was increased, 
the yield was reduced substantially from 56% to a mere 7.9% when there was a 2 molar 
equivalent of water. The reaction significantly favoured the anti-conformation as 
opposed to syn throughout the entire experiment, implying that steric hinderance 
reduced the ability of the syn-conformation (Table 3.6). Due to such low yields, the 
enantiomeric excess was not measured. Further studies are required in order to 
optimise the use of PAEPKI-NH-C16H33 as an organocatalyst in aldol reactions, with a 
particular focus on increasing the yield in the presence of water.  
 
 
 
 
Scheme 3.1. Reaction mechanism to show the direct asymmetric aldol reaction of p-
nitrobenzaldehyde and cyclohexanone, catalysed by an L-proline derived amphiphilic catalyst, 
PAEPKI-NH-C16H33, in the presence of water.  
PAEPKI-NH-C16H33 
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Table 3.6. Experimental results of the direct asymmetric aldol reaction of p-
nitrobenzaldehyde and cyclohexanone using an L-proline derived amphiphilic catalyst. 
 
Entrya 
Conc. Cat. 1 
(mol%) 
Cyclohex. 
(eq.) 
H2Ob(eq.) Yieldc(%) anti:sync ee (%) 
JP7 5 12 2.0 7.9 78:22 --- 
JP8 5 12 1.0 8.7 81:19 --- 
JP9 5 12 --- 56 84:16 --- 
 
a The reactions were made at room temperature with vigorous stirring  for 24 hours. 
b Water excess in relation to cyclohexanone (v/v). 
 
c The yield and diastereoselectivity were obtained by RMN-1H analysis of the gross 
product. 
 
 
3.3  Conclusion 
In summary, adding a lipid tail to the N-terminus of the PYY3-36 peptide fragments drives 
self-assembly into micelles, above a critical micelle concentration. Fluorescence 
spectroscopy using ANS as the fluorescent probe revealed low cmc values. Interestingly 
no cmc was obtained for the unmodified peptides, suggesting that lipidation is the 
driving force of aggregation due to the increased amphiphilicity. Temperature-
dependent measurements of the cmc show, unexpectedly, that micellization is 
essentially athermal showing that the process is driven by the favourable entropy 
change, associated with the hydrophobic effect as in protein folding. Further 
fluorescence studies using bovine serum albumin (BSA), showed that both lipidated 
peptide fragments interacted with BSA. 
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CD results showed the two N-terminal lipopeptides to have disordered conformations. 
Remarkably, C16IKPEAP and C16IKPEAPGE form β-sheet fibrils on drying, pointing to the 
formation of “amyloid-like” structures under these “denaturation” conditions. Possibly 
for lipopeptides as is proposed for proteins, amyloid may represent a common stable 
native state.32  
SAXS and cryo-TEM showed a micelle morphology for both lipidated peptides 
throughout the pH range studied (pH 2-12). No aggregated structures were observed for 
the native peptides. SAXS data was fitted to a spherical shell form factor for the lipidated 
fragments, indicative of micelle morphology, and the unlipidated fragments were fitted 
to a generalized Gaussian coil form factor, representative of peptide monomers in 
solution. There are definitive differences in the outer radius values as a function of pH 
of the micelle structures. The micelle radius values at pH 8 were significantly smaller for 
both lipidated peptides than at the other pH values, and this could be related to the loss 
of charge on the lysine residue at pH 8, causing an increase in net negative charge in the 
micelle, therefore reducing the size. The dimensions obtained from SAXS form factor fits 
are very similar for both lipidated peptides at a given pH. Also the Gaussian coil form 
factor parameters for the two unlipidated peptides are similar when at the same pH. 
Both unlipidated peptides did not self-assemble into ordered aggregated 
nanostructures which suggests that the C16 lipid tail is the driving force behind self-
assembly due to the increase in amphiphilicity in the peptide, causing hydrophobic 
collapse of the lipid tail to face away from the aqueous environment. 
In a different direction, we investigated the utility of L-proline to act as a catalyst in the 
IKPEAP sequence, with lipidation at the C-terminus (PAEPKI-NH-C16H33). The peptide as 
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expected, self-assembled into micelles above a cmc. Fluorescence experiments using 
ANS and pyrene found the cmc to increase with increased pH, suggesting that the 
peptide becomes less hydrophobic as the pH is increased. 
CD results interestingly showed a partial α-helical structure at 20 o C, which rapidly 
transitioned to a disordered structure when the temperature was raised above 40 o C. 
After two heat cycles it was found that PAEPKI-NH-C16H33 was only partially thermally 
reversible unlike C16IKPEAP which was fully reversible, suggesting that lipidation at the 
C-terminus is less thermally stable than at the N-terminus. Similar to the N-terminal 
lipidated peptide (C16IKPEAP), PAEPKI-NH-C16H33 SAXS data was fitted to a spherical 
shell form factor fitting, and XRD showed β-sheet structures. Unlike the N-terminal 
lipidated peptides, the radius values of PAEPKI-NH-C16H33 actually increase when 
increasing the pH to pH 8, further emphasizing the impact of lipidation position, as well 
as the ‘free’ proline residue on aggregation behaviour.   
Cytocompatibility studies using MTT assays found PAEPKI-NH-C16H33 to be cytotoxic to 
HCT-116 colorectal tumour cells at values close to the cmc and above. 
The use of PAEPKI-NH-C16H33 as an organocatalyst in aldol reactions was found to be 
moderately successful, with yields of 56% in the absence of water. Increasing the 
amount of water to the reaction vessel reduced the efficiency of the peptide catalyst 
significantly, with yields as low as 7.6%. Further experiments are required to optimise 
the use of PAEPKI-NH-C16H33 as a catalyst in the reaction. 
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Overall these findings are a promising starting point in understanding the self-assembly 
of the full PYY3-36 peptide sequence as a function of pH and temperature, in the 
development of a therapeutic agent to treat obesity and type II diabetes.  
 
3.4  Materials and Methods 
Materials. IKPEAP (TFA salt) was synthesised by Biomatik, Canada. The molecular weight 
by mass spectrometry was 653.8 gmol-1 (expected: 653.37 gmol-1) and the purity by 
HPLC was 99.8 %. 
IKPEAPGE (TFA salt) was synthesised by Biomatik, Canada. The molecular weight by mass 
spectrometry was 839.98 gmol-1 (expected: 839.44 gmol-1) and the purity by HPLC was 
99.7 %. 
C16IKPEAP (ammonium acetate salt) was synthesised by Peptide Synthetics, UK. The 
molecular weight by mass spectrometry was 892.179 gmol-1 (expected: 891.60 gmol-1) 
and the purity by HPLC was > 95.0 %. 
C16IKPEAPGE (ammonium acetate salt) was synthesised by Peptide Synthetics, UK. The 
molecular weight by mass spectrometry was 1078.346 gmol-1 (expected: 1077.67 gmol-
1),  and the purity by HPLC was > 95.0 %. 
PAEPKI-NH-C16H33 (TFA) was synthesised by Peptide Synthetics, UK. The molecular 
weight by mass spectrometry was 877.204 gmol-1 (expected: 876.64 gmol-1) and the 
purity by HPLC was > 95.0 %. 
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Methods 
Fluorescence Spectroscopy. Fluorescence spectra were recorded with a Varian Cary 
Eclipse fluorescence spectrometer (Varian IEEE-488, Australia) with samples in 4 mm 
inner quartz cuvettes. The ANS assays were performed using 3.25 x 10-4 to 0.13 wt% 
peptide, in 2.1 x 10-3 wt% 8-anilino-1-napthalenesulfonic acid (ANS) solution. The 
samples were excited at λex = 356 nm, and the fluorescence emission was measured for 
λ = 400−670 nm. Pyrene assays were performed using 3.25 x10-4 to 0.13 wt% peptide, in 
2.167 x 10-5 wt % pyrene solution. The samples were excited at λex = 339 nm, and the 
fluorescence emission was measured for λ = 360−500 nm. 
Temperature-dependent fluorescence assays of cmc were carried out using the same 
method but a temperature controlled water bath was also used and measurements 
were collected in the temperature range 20-70 o C. 
Circular Dichroism (CD). CD spectra were recorded using a Chirascan spectropolarimeter 
(Applied Photophysics, UK). Spectra are presented with absorbance A < 2 at any 
measured point with a 0.5 nm step, 1 nm bandwidth, and a 1 s collection time per step. 
The CD signal from the background was subtracted from the CD signal of the sample 
solution. Ellipticity is reported as the mean residue ellipticity ([θ], in deg cm2 dmol-1) and 
calculated as: 
[θ] = [θ]obs MRW/10cl 
Where [θ]obs is the ellipticity measured in millidegrees, MRW is the mean residue 
molecular weight of the peptide (molecular weight divided by the number of amino acid 
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residues), c is the concentration of the sample in mg/mL, and l is the optical path length 
of the cell in centimeters. 
CD spectra were measured in the temperature range 20-70 oC, using a 10 oC 
temperature step. Samples were equilibrated at each temperature for 2 minutes before 
measurements were recorded. Quartz plaques (0.1 and 0.01 mm thick) were used for 
the experiments and a pH range of 2-12 was measured. 0.1-1 wt% samples were used. 
Experiments were carried out in D2O. CD spectra were also measured on dried peptides 
using quartz plates (0.01 mm). 
Small-Angle X-ray Scattering (SAXS). Solution and dried SAXS experiments were 
performed on the bioSAXS beamline BM29 at the ESRF, Grenoble, France, and the 
bioSAXS beamline B21 at Diamond light source, U.K. Solutions containing 0.162-1 wt% 
C16IKPEAPGE and IKPEPAGE, and 0.134-1 wt% of C16IKPEAP and IKPEAP were loaded in 
PCR tubes in an automated sample changer. SAXS data were collected using a Pilatus 1 
M detector. The sample−detector distance was 2.84 m. The X-ray wavelength was 0.99 
Å. The wavenumber q = 4π sin θ /λ scale was calibrated using silver behenate, where λ 
is the x-ray wavelength and 2θ is the scattering angle. Dried SAXS measurements were 
performed by drying the peptides onto Kapton tape, and inserting them into a gel cell. 
Data was collected using a Pilatus 2M detector at a fixed camera length of 3.9 m with a 
wavelength λ= 1 Å. The wavenumber q = 4π sin θ /λ scale was calibrated using silver 
behenate, where λ is the x-ray wavelength and 2θ is the scattering angle. 
Fiber X-ray Diffraction (XRD). XRD was performed on peptide stalks prepared by 
drawing a fibre of peptide solution between the ends of wax-coated capillaries. 3 wt% 
peptide solutions were used for IKPEAP and IKPEAPGE, and 5 wt% peptide solutions for 
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C16IKPEAP and C16IKPEAPGE.  After drying, the capillaries were separated and a stalk was 
left on the end of one of the capillaries. Stalks were vertically mounted onto the 
goniometer of an Oxford Diffraction Gemini Ultra instrument, equipped with a Sapphire 
CCD detector. The sample to detector distance was 44 mm. The X-ray wavelength was λ 
= 1.54 Å. The wavenumber scale (q = 4π sin θ/λ where 2θ is the scattering angle) was 
geometrically calculated. The software CLEARER33 was used to reduce the 2D data to a 
one dimensional intensity profile.  
Dynamic Light Scattering (DLS). Experiments were performed using an ALV CGS-3 
system with a 5003 multidigital correlator. The light source was a 20 mW HeNe laser, 
linearly polarized, with λ = 633 nm. Samples were filtered through 0.20 µm Anotop 
organic membrane filters from Whatman into standard 0.5 cm diameter cylindrical glass 
cells.  
Cryogenic Transmission Electron Microscopy (Cryo-TEM). Imaging was carried out using 
a field emission cryo-electron microscope (JEOL JEM-3200FSC) operating at 200 kV. 
Images were taken using bright-field mode and zero loss energy filtering (omega type) 
with a slit width of 20 eV. Micrographs were recorded using a CCD camera (Gatan 
Ultrascan 4000, USA). The specimen temperature was maintained at -187 oC during the 
imaging. Vitrified specimens were prepared using an automated FEI Vitrobot device 
using Quantifoil 3.5/1 holey carbon copper grids, with a 3.5 μm hole sizes. Grids were 
cleaned using a Gatan Solarus 9500 plasma cleaner just prior to use and then transferred 
into the environmental chamber of a FEI Vitrobot at room temperature and 100% 
humidity. Following this, 3 μL of sample solution at 1 wt % concentration was applied on 
the grid, blotted once for 1 s, and then vitrified in a 1/1 mixture of liquid ethane and 
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propane at −180 °C. Grids with vitrified sample solutions were maintained in a liquid 
nitrogen atmosphere and then cryo-transferred into the microscope. 
Transmission Electron Microscopy (TEM). Imaging of dried films was performed using a 
2100 plus TEM instrument. A thin film of peptide was added (0.134 wt% of C16IKPEAP 
and 0.162 wt% C16IKPEAPGE) to the surface of a carbon film coated TEM grid and stained 
with 1 wt% uranyl acetate solution for 1 minute, followed by washing with distilled 
water by, applying enough water to cover the grid and leaving it for 1 minute. The grids 
were then taken and placed in the TEM Instrument and images were taken, using a 4.0 
megapixel CMOS camera, at various magnifications.  
Cytocompatibility studies using an MTT assay. The cytotoxicity of PAEPKI-NH-C16H33 
was examined. In vitro cell culture was carried out using the HCT-116 human colorectal 
tumour cell line. Cells were cultured in MCcoys 5A modified medium with with 10% fetal 
bovine serum (FBS), and 1% antibiotic-antimycotic (Thermoscientific, 100×). Cells were 
maintained in a humidified atmosphere of 5% CO2 at 37 °C. Cell viability effects were 
examined using the MTT 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay. The peptide was dissolved in complete medium. Cells were seeded into a 96-well 
plate at a seeding density of 4 × 104 cells/mL, and allowed to adhere for 24 h in 100 μL 
complete medium. After 24 h, a total volume of 100 μL of either complete medium 
and/or peptide solution was added, to give final peptide concentrations of 0.06, 0.02, 
0.008, 0.00173, 0.004, 0.0008 or 0.0004wt % peptide. Negative controls of peptide in 
complete medium with no cells were included. After 67 h of incubation, 20 μL of MTT 
(0.5 wt % in PBS) was added to each well plate and allowed to incubate for 5 h (total of 
72 h incubation). After this, the solutions were removed from the wells and replaced 
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with 100 μL DMSO per well in order to dissolve the formazan crystals. Plates were 
incubated for 30 min, and then analyzed using a UV microplate reader (λ = 570 nm). 
Results are reported [(treated cells − negative control)/(untreated cells)] × 100. 
Aldol reactions in water. Cyclohexanone (0.9 mmol, 90 µL) was added to the peptide 
catalyst (3.6 µmol, 3.2 mg), varying the amount of water (170 µL, 85 µL, and 0 µL). p-
nitrobenzaldehyde (72.7 µmol, 10.3 mg) was added the reaction mixture was stirred at 
room temperature for 24 hours, before being extracted with ethyl acetate four times. 
For the experiment containing no water, 0.5 mL of water was added to the system 
before extracting, to help in the phase separation. NMR measurements in (1H) Bruker 
Ultrashield 300 was performed in 300 MHz, using the deuterated chloroform solvent. 
The yield and diastereomers anti:syn ratio were calculated using the NMR spectrum 
obtained, where tetramethylsilane (TMS) was used as a reference. 
1H NMR (300 MHz, CDCl3): δ 8.22-8.18 (m, 2H, ArH); 7.51-7.47 (m, 2H, ArH); 5.47 (br s, 
1H, CHOH-syn); 4.89 (dd, J = 7.5 Hz, 3.0 Hz, 1H, CHOH-anti); 4.08 (d, J = 3.0 Hz, 1H, CHOH-
anti); 2.66-2.30 (m, 1H, CHCHOH); 2.66-2.30 (m, 2H, CH2C(O)); 2.16-1.24 (m, 6H, chex-
H). 
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Chapter 4 - The Effect of Lipidation on the Self-Assembly of a 
Truncated Peptide Fragment Derived from the Gut Hormone 
PYY3-36 
 
4.1 Introduction 
 
The use of short peptides in the treatment of disease is very attractive due to relative 
ease of synthesis and cost in comparison to larger peptide therapeutics.1 Truncated 
peptide fragments provide a cost effective way of investigating peptide behaviour, and 
to study isolated sections in more detail, to fully understand important aspects such as 
self-assembly, binding affinity, and bioactivity. In one example, Kumar et al. found that 
a truncated pentapeptide had a higher affinity for a Casitas B-Lineage Lymphoma (Cbl) 
tyrosine kinase binding domain than the parent peptide.2 Another study by Swedberg et 
al. discovered that a C-terminal truncation of exendin-4, with removal of the nine C-
terminal residues, had little effect on cAMP signalling when compared to the native 
peptide.3 Exendin-4 is an exogenous GLP-1R agonist with a similar pharmacological 
profile to GLP-1, and therefore of relevance here since it is a gut hormone, similar to 
PYY3-36. 
In this chapter the self-assembly of another truncated fragment derived from PYY3-36 is 
investigated. PYY3-36 is known to have a predominant alpha-helical secondary structure 
in solution, and aggregates into long inter-tangling fibres at its native pH in water.4 The 
peptide sequence studied here lies within the β-turn and α-helical section, making it 
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very interesting in terms of its self-assembly and aggregation behaviour. The full peptide 
sequence of PYY3-36 is shown in Figure 4.1a, with the peptide to be studied, EELNRYY, 
highlighted in red. The effect of palmitoyl lipidation at the N-terminus is also examined 
in order to determine the impact of increased amphiphilicity on self-assembly and 
stability. Furthermore, gelation properties are investigated, and cytocompatibility 
studies are carried out using the HCT-116 cancer cell line. The amino acid sequence of 
the lipidated and native peptide fragments, along with their chemical structures, are 
shown in Figure 4.1.  
 
 
Figure 4.1. a) Amino acid sequence and chemical structure of PYY3-36, showing the 
different domains, and highlighting EELNRYY. b) Amino acid sequence and chemical 
structure of EELNRYY. c) Amino acid sequence and chemical structure of C16EELNRYY. 
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4.2 Results and Discussion 
The presence of a critical aggregation concentration (cac) was firstly investigated using 
pyrene as a fluorescent probe. As previously mentioned, pyrene has been used a 
number of times to detect the cac of peptides and amphiphilic molecules.5-6 A plot of 
the I1 (373 nm) intensity versus concentration was used to assign the cac, with the I1 
peak corresponding to the first vibronic band of pyrene. Results indicate an increase in 
cac with increased pH, with values of 0.0034 wt%, 0.046 wt% and 0.15 wt% at pH 7, 10, 
and 12 respectively for C16EELNRYY (Figure 4.2). The increase in cac with pH indicates 
reduced hydrophobicity at pH 12 due to tyrosinate ions being present at high pH. No cac 
was observed for the unlipidated peptide fragment itself, demonstrating a lack of 
aggregation. It is believed that the increased amphiphilicity caused by the alkyl chain 
helps to drive the aggregation due to the hydrophobic effect.7-8 A summary of cac values 
is shown in Table 4.1. 
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Figure 4.2. Fluorescence using pyrene to determine the critical aggregation 
concentration (cac) of C16EELNRYY in the pH range 7-12. The point of intersection 
defines the cac. I1= the intensity value at 373 nm. 
 
Table 4.1. Summary of cac values (wt %) of C16EELNRYY in the pH range 7-12. 
 pH7 (wt%) pH10 (native pH) (wt%) pH12 (wt%) 
C16EELNRYY 0.0034 0.046 0.15 
 
Circular dichroism spectroscopy was used to examine the secondary structure of the 
native and lipidated peptides at pH 9 and 20 o C. At pH 9 and above, both peptides were 
clear in solution, but below this pH, the lipidated peptide formed a precipitate. The 
native peptide appeared to have a disordered secondary structure with a minimum at 
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195 nm, whilst the lipidated truncated fragment exhibited a spectrum characteristic of 
a β-sheet structure with a minimum at around 218 nm, and positive ellipticity at 195nm 
(Figure 4.3). Temperature ramp experiments were also carried out for C16EELNRYY from 
20-70 o C, and the results show that the β-sheet structure is retained throughout this 
temperature range (Figure 4.4). A further CD experiment was performed to study the 
pH stability of the lipidated peptide in the pH range 7 (native pH) to pH 12. At high pH, 
tyrosine becomes charged tyrosinate, the conjugate phenolate base of tyrosine,9 and 
the resulting CD spectra shows a significantly reduced molar ellipticity, that is only 
partially reversible upon returning the pH back to 7. This indicates that the peptide 
undergoes some degradation in highly alkaline conditions. 
At pH 12, the peptide carries a highly negative charge of -6, calculated using innovagen 
software; 10 therefore charge repulsion was expected to interrupt secondary structure. 
The results in Figure 4.5 confirm this, and upon pH change from pH 7 to pH 12, there is 
a transition in secondary structure from β-sheet to disordered. Lowering the pH back 
down to 7 indicates only partial reversibility back to β-sheet, with molar ellipticity values 
at the 216 nm minimum, much less negative than before the pH change. 
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Figure 4.3. CD spectra of C16EELNRYY and EELNRYY at 1 wt%, 20 o C and pH 9. 
 
 
 
 
 
 
 
 
 
150 
 
Figure 4.4. CD spectra of C16EELNRYY at 1 wt%, from 20 -70 o C at pH 9. 
 
 
 
 
 
 
 
 
Figure 4.5. CD spectra of C16EELNRYY to show secondary structure reversibility after 
two pH switch cycles from native pH to pH 12 at 20 o C. 
  
Cryo-TEM and SAXS were used to further explore the self-assembly of the truncated 
peptide fragments. Cryo-TEM images of C16EELNRYY revealed fibers at native pH (pH 7), 
clusters of micelles at pH 10, and nanosheets at pH 12 (Figure 4.6). As expected, no 
defined structures were observed for EELNRYY since it does not have a cac, and 
representative images are shown in Figure 4.7. SAXS was used to compliment cryo- TEM 
and scattering profiles of both peptides are shown in Figure 4.8. C 16EELNRYY data was 
fitted to a long cylindrical shell form factor at pH 7 (native pH), and a spherical shell form 
factor at pH 10, representative of fibers and micelles respectively. Data at pH 12 was 
fitted to a combination of a bilayer Gaussian and generalized Gaussian coil form factor 
(10:90 % ratio respectively). This was due to cryo-TEM images revealing the presence of 
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nanosheets, but the SAXS intensity profile indicating a mixture of monomers and nano-
sheets from the scattering shape at low q being similar to that of a monomer. The native 
peptide, EELNRYY was fitted to a generalized Gaussian coil form factor, to show 
monomers. There is a significant structure factor peak at q = 0.05 Å-1 for C16EELNRYY at 
pH 10, showing interactions between the micelles, consistent with cluster formation. 
Fitted parameters are shown in Tables 4.2-4.6. 
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Figure 4.6. cryo-TEM images of C16EELNRYY at 1 wt% in H2O. a) native pH (pH 7) 
showing fibers, b) pH 10 showing clusters of micelles, c) pH 12 showing nanosheets. 
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Figure 4.7. Cryo-TEM images of EELNRYY at 1 wt% in H2O. a) native pH (pH 3), b) pH 10, 
c) pH 12. There is a lack of aggregation throughout the pH range studied. 
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Figure 4.8. SAXS intensity profiles and form factor fittings of a) EELNRYY in the pH range 
3-12. Data was fitted to a generalized Gaussian coil form factor fitting representative of 
monomers. b) C16EELNRYY in the pH range 7-12. Data was fitted to a long cylindrical shell 
form factor at pH 7, a spherical shell at pH 10, and a combination of generalized Gaussian 
coil and bilayer Gaussian at pH 12. 
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Table 4.2. SAXS form factor parameters of EELNRYY (1 wt%) in the pH range 3-12 fit to 
a generalized Gaussian coil form factor model using SASfit. Key: BG = background, N= 
scaling factor, Rg = radius of gyration, ν = Flory exponent, I0 = forward scattering. 
 
 
 
Table 4.3. SAXS form factor parameters of C16EELNRYY (1 wt%) at pH 7 fit to a long 
cylindrical shell model using SASfit. Key: BG = background, N = scaling factor, σ = 
Gaussian width, R = inner radius, DR =shell thickness, L = length of cylinder, ηcore = 
scattering contrast of core, ηshell= scattering contrast of shell, ηsolv= scattering contrast 
of solvent. 
 
Sample BG N/arb. 
units 
σ/ 
nm 
R/ 
nm 
DR/ 
nm 
L/   
nm 
ηcore ηshell ηsolv 
C16EELNRYY 
pH 7 
2.22x10-4 2.11x10-8 5.46 24.8 0.65 500 1.50x10-2 0.15 1.60x10-2 
 
 
 
Sample BG N/arb. 
units 
Rg / nm v I0 
EELNRYY pH3 
(native pH) 
5x10-4 0.988 7.17 0.316 7.4x10-3 
EELNRYY pH7 -1.8x10-3 1.27 6.98 0.877 8.6x10-3 
EELNRYY pH10 1x10-4 0.643 6.32 0.327 8.8x10-3 
EELNRYY pH12 1.4x10-3 1.54 7.00 0.181 4.5x10-3 
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Table 4.4. SAXS form factor parameters of C16EELNRYY (1 wt%) at pH 10 fit to a spherical 
shell form factor model using SASfit. Key: BG = background, N= scaling factor, σ = 
Gaussian width, R1= inner radius, R2= outer radius, μ = scattering contrast of inner core, 
η = scattering contrast of shell. 
 
Sample BG N/arb. 
units 
σ/nm R1 / nm R2 / 
nm 
μ η core 
C16EELNRYY 
pH10 
2.75x10-4 1.00 5.22 16.77 9.83 -1.53 1.05x10-5 
 
Table 4.5. SAXS fitting parameters of C16EELNRYY (1 wt%) at pH 12 fit to a bilayer 
Gaussian form factor (10%). BG = background, N = scaling factor, σ = Gaussian width, t = 
bilayer thickness, σout = Scattering density of outer Gaussians, bout = width of outer 
Gaussians, σcore= scattering density of inner Gaussian, bcore= width of inner Gaussians D 
= diameter of disc (fixed parameter). 
 
Sample BG N / arb. 
units 
σ / 
nm 
t / 
nm 
σout bout σcore bcore D / 
nm 
C16EELNRYY 
pH12 
9.34x10-4 1.19x10-8 6.84 62.7 0.59 1.36x10-2 13.63 -1.5x10-3 500 
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Table 4.6. SAXS form factor parameters of C 16EELNRYY (1 wt%) at pH 12 fit to a 
generalized Gaussian coil form factor model using SASfit (90 %). Key: BG = background, 
N= scaling factor, Rg = radius of gyration, ν = Flory exponent, I0= forward scattering. 
 
Sample BG N / arb. 
units 
Rg / nm v I0 
C16EELNRYY 
pH12 
9.34x10-4 4.83x10-2 19.28 0.68 0.342 
 
The possibility of dityrosine formation in alkaline conditions was investigated using 
fluorescence spectroscopy, at pH 12. Dityrosine is easily recognised by an intense 
fluorescence peak at 400 nm, representative of its singly ionized form, by excitation at 
315 nm in alkaline conditions.11-12 The emission and excitation spectra of C16EELNRYY 
are shown in Figure 4.9. At pH 12, the emission spectrum shows a peak close to 400 nm, 
suggesting dityrosine formation, and this is not as prominent at native pH. This is 
because at high pH, the phenol hydroxyl group becomes deprotonated to form 
phenolate ions. The excitation spectrum also agrees with dityrosine formation due to a 
red shift from around 300 nm, to 320 nm.13 Results for the unlipidated peptide also show 
dityrosine formation (Figure 4.10). 
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Figure 4.9. Fluorescence of C16EELNRYY at pH 7 (native pH in water) and pH 12 to study 
dityrosine formation. a) Emission spectrum at λex= 315 nm. b) Excitation spectrum at 
λem= 410 nm. 
 
 
 
 
 
 
 
 
Figure 4.10. Fluorescence of EELNRYY at pH 2 (native pH in water) and pH 12 to study 
dityrosine formation. a) Emission spectrum at λex = 315 nm. b) Excitation spectrum at 
λem = 410 nm.  
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4.2.1 Hydrogel Studies 
 
Peptide hydrogels may be useful for many applications such as slow drug release 
delivery systems, regenerative medicine, the topical application of therapeutic peptides, 
or encapsulated drugs.14-17 The use of short peptide sequences provides this, in addition 
to lowering cost as previously mentioned. Hydrogel formation by lapidated peptides is 
rather uncommon, and few studies have been reported so far. As mentioned in chapter 
2, those that have been reported have been based on β-sheet nanofiber forming 
lipidated peptides that gelated via non-covalent intermolecular cross-linking.18-20  
Since C16EELNRYY was found to adopt a β-sheet structure, and contained two aromatic 
tyrosine residues, it was of interest to investigate its gelation properties. Increasing the 
concentration to 1 wt% and above allowed for the formation of a hydrogel for the 
lipidated peptide, with the gel forming at the peptides native pH in ultrapure water (pH 
7) (Figure 4.11). The theoretical isoelectric point calculated using Innovagen software, 
was 4.15, with the net charge being -1 at pH 7.10 At pH 7, the electrostatic charges are 
easily overcome, allowing the hydrophobic interactions, and π-π stacking of the tyrosine 
residues to drive gelation. It is however important to remember that the pKa values in 
peptides can shift upon aggregation, meaning that the exact charge on amino acid 
residues is very hard to quantify fully.21-22 Gelation was not observed for the native 
peptide. It was thought that the incorporation of a hydrophobic alkyl chain to the 
peptide influenced the β-sheet structure and enhanced fibril formation, by allowing 
minimal contact between the water and the hydrophobic alkyl chain.23 Therefore a 
combination of increased hydrophobicity, and π-π stacking of the tyrosine motifs was 
suggested to be the mechanism behind gelation. 
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Figure 4.11. Gel of C16EELNRYY at 1 wt% shown by the inverted vial method. 
 
CD and fiber X-ray diffraction (XRD) were used to study conformation, along with SAXS 
and TEM to probe the morphology. Rheology was then used to determine the 
viscoelastic properties of the gel (Figure 4.12). The strain sweep shows linear viscoelastic 
behaviour up to around 1 % oscillation strain, and the frequency sweep at a fixed strain 
of 0.6 % shows that the moduli exhibit only a weak dependence on frequency. 
Furthermore, G’ > G”, and the magnitude of G’ is significantly high compared to a fluid, 
consistent with a solid like structure (Figure 4.12b). Temperature ramp experiments 
were also measured and results showed that the gel was stable throughout the 
temperature range studied (20-40 o C) with both moduli not significantly changing 
(Figure 4.13). Further stability studies were carried out on the lipidated peptide hydrogel 
to investigate its reversibility. Firstly, the pH was decreased to pH 2.95 to break up the 
gel into insoluble peptide clumps and water. The pH was then raised to a value close to 
the peptide’s native pH (pH 6.95). Results found that the gel re-formed within a few 
hours. Next, the gel was heated to 55 o C, where the gel transitioned into a viscous liquid. 
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Upon cooling the gel re-formed. These results indicate full reversibility of the hydrogel 
to changes in pH and temperature. 
 
 
Figure 4.12. Dependence of G′ and G″ at 20 o C and 1 wt% on the: a) oscillatory strain, 
and b) angular frequency, with the oscillation strain fixed to 0.6 % which lies within the 
linear regime. 
 
 
 
 
 
 
 
 
Figure 4.13. Temperature ramp of the dynamic shear moduli of C16EELNRYY from 20-
40 o C, showing stability of G’ with temperature. 
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CD spectra from gels of the lipidated peptide fragment at pH 7, from 20-70 o C are shown 
in Figure 4.14a, and the data shows a β-sheet like spectrum with a minimum close to 
210 nm over the whole temperature range. Fiber XRD intensity profiles are shown in 
Figure 4.14b and the results indicate a β-sheet structure for the lipidated peptide, with 
the d-spacings of 4.68 Å being associated with the spacing between two β-strands in the 
same β-sheet.25 XRD data of the native peptide also has d-spacings of 4.68 Å, suggesting 
a change in conformation from disordered to a β-sheet structure upon drying. TEM 
images of the peptide gel show a network of entangled fibers (Figure 4.14c). This 
compares to the cryo-TEM images at native pH, where fibers were also observed. 
However, there was a substantial amount of time between when the sample was 
prepared, and when cryo-TEM was carried out, and it was thought that the peptide had 
already gelled by the time the images were produced. As a result it is believed that both 
cryo-TEM and TEM images are of the lipidated hydrogel. The SAXS intensity profile of 
the gel is shown in Figure 4.14d and data was fitted to a long cylindrical shell form factor, 
typically used for fibrils (Table 4.6). 
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Figure 4.14. a) Gel CD of C16EELNRYY at 1 wt% at pH 7 from 20-70 o C. b) Fibre X-ray 
diffraction intensity profile of EELNRYY and C16EELNRYY at native pH, with Bragg spacing 
of 4.68 Å. c) TEM images of C16EELNRYY gel at 1 wt% showing a network of fibers at 
native pH. d) SAXS data of C16EELNRYY gel at 1 wt% fit to a long cylindrical shell form 
factor. 
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Table 4.6. SAXS form factor parameters of C16EELNRYY gel (1 wt% and pH 7) fit to a long 
cylindrical shell form factor model using SASfit. Key: BG = background, N = scaling factor, 
σ = Gaussian width, R = inner radius, DR =shell thickness, L = length of cylinder, ηcore = 
scattering contrast of core, ηshell= scattering contrast of shell, ηsolv= scattering contrast 
of solvent. 
 
Sample BG N / arb. 
units 
σ/ 
nm 
R/  
nm 
DR/ 
nm 
L/  
nm 
ηcore ηshell ηsolv 
C16EELNRYY 
gel pH7 
8.4x10-3 2.72x10-9 3.25 17.43 14.8 500 1.23x10-3 1.27x10-3 1.23x10-3 
 
4.2.2 Cytocompatibility Studies 
 
4.2.3 Assay Development 
 
Cells have four distinct growth phases: lag phase, exponential phase, stationary phase, 
and death phase. During the lag phase cells adjust to their environment and start to 
increase in size, before entering the exponential phase where they continue to grow and 
divide but at a constant pace. Following this, the cells enter the stationary phase where 
their growth plateaus and cell death and proliferation become equal. Finally, the death 
phase occurs where the rate of cell death is higher than cell proliferation and cell 
viability declines at an exponential rate. 
A growth curve experiment was carried out prior to the cell studies using peptide 
concentrations ranging from 5 x 103 to 8 x 104 cells per mL, to ensure that cells were 
within the exponential growth phase in the experiment, and thus determine a suitable 
cell density value. The density chosen was 4 x 104 cells per mL since the cells were still 
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in the growth phase at this concentration, making it a viable value (Figure 4.15). 
However due to the aggressive nature of the cell line, when MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added, it metabolized to 
formazan crystals of an extremely high density, giving rise to crystal de-attachment from 
the bottom of the 96-well plate. This resulted in underestimation of viable cell numbers. 
As a result, the experiments were repeated with a lower cell density of 1 x 104 (still in 
the growth phase) by C.J.C Edwards-Gayle, University of Reading. Results followed a 
similar trend, and the lipidated peptide was significantly more cytotoxic than the native 
peptide. Cytocompatibility studies on the full PYY3-36 sequence using Caco-2 cells 
(another colon cancer cell line) have been reported, and PYY3-36 was not found to exert 
any cytotoxic effects.26 As a result, the studies presented here of the truncated PYY3-36 
fragment, provide a good judgment of how lipidated analogues of the full peptide 
sequence would behave under the same conditions. 
 
 
 
 
 
 
 
Figure 4.15. Growth curve data using HCT-116 cells over a 6-day period, to calculate a 
suitable cell density for cytocompatibility studies. 
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4.2.4 MTT Assay on a HCT-116 Cell Line 
 
Cytocompatibility studies of C16EELNRYY, and EELNRYY, were performed using an MTT 
((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay on human 
colorectal tumour cells (HCT-116 cell line), to determine cell viability (Figure 4.16-4.17). 
This cell line was used with it being a gut cell line, and therefore of interest to EELNRYY 
and C16EELNRYY since they are gut derived peptide fragments. The IC50 (half maximal 
inhibitory concentration) was found to be 0.061 wt% for C16EELNRYY. Above this 
concentration there is a significant decrease in cell proliferation, with only around 20 % 
of cells still viable. An IC50 value was not obtained for native EELNRYY due to more than 
50 % of the cells being viable throughout the concentration range studied. These results 
are interesting and indicate that the lipidated peptide is significantly more cytotoxic 
than the native peptide at concentrations above the cac, suggesting that peptide 
aggregation is causing the peptide to become cytotoxic. Further studies to investigate 
this further are required to gain a more in-depth knowledge. It would also be useful to 
carry out work on a non-cancer based gut cell line to compare cytotoxicity between the 
two. 
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Figure 4.16. Absorbance as a function of peptide concentration of EELNRYY and 
C16EELNRYY to show cell viability. 
 
 
Figure 4.17. % cell viability of HCT-116 cells after treatment with a) EELNRYY, b) 
C16EELNRYY. 
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4.3 Conclusion 
 
In this chapter the self-assembly and cytotoxicity of an N-terminal lipidated peptide 
fragment of the gastrointestinal peptide hormone PYY3-36 has been examined, and 
compared to the unlipidated fragment. Fluorescence studies using pyrene successfully 
determined the cac of C16EELNRYY, however no cac was obtained for EELNRYY, 
suggesting that the increased amphiphilic nature of the lipidated peptide favoured 
aggregation. Circular dichroism spectroscopy showed distinct differences between the 
lipidated peptide and the native peptide, with the lipidated peptide having a β-sheet 
secondary structure and the native peptide having a disordered structure. SAXS and 
cryo-TEM further enhanced the differences between the two peptides, with cryo-TEM 
and SAXS of the lipidated peptide showing a range of aggregated structures from micelle 
clusters, to fibrils, to nanosheets depending on pH. No distinct aggregated structures 
were observed for the native peptide. Unexpectedly, the lipidated peptide was found to 
form a hydrogel at native pH (pH 7) and at 1 wt %. The charge on the peptide at this pH 
was calculated to be -1 using web based software.10 The mechanism behind gelation 
was attributed to π- π stacking of the tyrosine residues, along with the lipid chain 
favouring a β-sheet structure, allowing for the formation of cross-linked fibrils, leading 
to gelation. Rheological studies found G’ to be substantially higher than a typical fluid, 
suggesting a hard gel structure. 
Cytotocompatibility studies using the HCT-116 cell line found the lipidated peptide to be 
cytotoxic at concentrations above the cac. The native peptide was not found to be 
significantly toxic, with more than 50 % of the cells still viable throughout the 
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concentration range studied. As a result, it is thought that aggregation leads to 
cytotoxicity. 
4.4 Materials and Methods 
 
Materials. Palmitoyl-EELNRYY (ammonium acetate salt) was synthesised by Peptide 
Synthetics, Fareham. UK. The molecular mass by API-ES was 1224.451 g mol-1 (expected 
1223.68 g mol-1), with a purity of 96.4 % determined by HPLC. 
EELNRYY (TFA salt) was synthesised by Peptide Synthetics, Fareham. UK. The molecular 
mass by API-ES was 986.031 g mol-1(expected 985.45g mol-1), with a purity of 95.3 % 
determined by HPLC. 
Fluorescence Spectroscopy. The critical aggregation concentration experiments were 
determined using a Varian Cary Eclipse fluorescence spectrometer (Varian IEEE-488, 
Australia) with samples in 4 mm inner quartz cuvettes. Pyrene was used as the 
fluorescent probe, and assays were performed using 1.0 x 10-2 to 0.3 wt% peptide, in 
2.167 x 10-5 wt% pyrene solution. The samples were excited at λex = 339 nm, and the 
fluorescence emission was measured for λ = 360−500 nm. Dityrosine formation was 
investigated at native pH (pH 7) and pH 12. Fluorescence experiments were measured 
for water and 0.1 wt% peptide solutions. Samples were measured in a 1.0 cm path- 
length quartz cuvette, and the slit width was 5 nm. Emission spectra were recorded at 
λex = 315 nm from 340 to 600 nm, and excitation spectra were recorded at λem = 410 nm, 
from 250-410 nm. Five measurements were taken for each, and the background was 
subtracted. 
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Circular Dichroism (CD). CD spectra were recorded using a Chirascan 
spectropolarimeter (Applied Photophysics, UK). Spectra are presented with absorbance 
A < 2, with a 0.5 nm step, 1 nm bandwidth, 1 s collection time per step, and 3 repeats. 
The CD signal from the background (water) was subtracted from the CD signal of the 
sample solution. Ellipticity is reported as the mean residue ellipticity ([θ], in deg cm2 / 
dmol) and calculated as:  
[θ] = [θ] obs MRW/10cl  
Where [θ] obs is the ellipticity measured in millidegrees, MRW is the mean residue 
molecular weight of the peptide (molecular weight divided by the number of amino acid 
residues), c is the concentration of the sample in mg/mL, and l is the optical path length 
of the cell in centimeters. 
Samples were measured using quartz plaques (0.1 mm spacing) with 1 wt% solution 
concentration in the pH range 9-10. CD spectra were measured using a temperature 
range of 20-70 o C with 10 o C increments. The sample was equilibrated at each 
temperature for 2 minutes before measurements were recorded. 
Cryogenic Transmission Electron Microscopy (cryo-TEM). Imaging was carried out using 
a field emission cryo-electron microscope (JEOL JEM-3200FSC) operating at 200 kV. 
Images were taken using bright-field mode and zero loss energy filtering (omega type) 
with a slit width of 20 eV. Micrographs were recorded using a CCD camera (Gatan 
Ultrascan 4000, USA). The specimen temperature was maintained at -187 o C during the 
imaging. Vitrified specimens were prepared using an automated FEI Vitrobot device 
using Quantifoil 3.5/1 holey carbon copper grids, with a 3.5 μm hole size. Grids were 
cleaned using a Gatan Solarus 9500 plasma cleaner just prior to use and then transferred 
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into the environmental chamber of a FEI Vitrobot at room temperature and 100 % 
humidity. Following this, 3 μL of sample solution at 1 wt % concentration was applied 
on the grid, blotted once for 1 s, and then vitrified in a 1:1 mixture of liquid ethane and 
propane at −180°C. Grids with vitrified sample solutions were maintained in a liquid 
nitrogen atmosphere and then cryo-transferred into the microscope. 1 wt% samples in 
the pH range 7-12 were imaged. 
Small Angle X-ray Scattering (SAXS). Solution SAXS measurements were carried out on 
the bioSAXS beamline B21 at Diamond, Harwell, UK. Peptide solutions (1 wt% in the pH 
range of 9-10) in water were loaded into PCR tubes in an automated sample changer. 
Data was collected using a 2 M detector and at a fixed camera length of 3.9 m with a 
wavelength λ = 1 Å. The wavenumber q = 4π sin θ /λ scale was calibrated using silver 
behenate, where λ is the x-ray wavelength and 2θ is the scattering angle. 
Rheology. Gel properties were investigated using an AR-2000 rheometer. Experiments 
were performed using a plate-and-plate geometry (plate radius = 20 cm; gap = 400 μm). 
The linear regime of the sample was first identified from the dependence of the storage 
(G′) and loss (G″) moduli on the oscillation strain at a fixed frequency of 1 Hz. The 
dependence of G′ and G″ on the angular frequency was then determined at a fixed 
oscillatory strain of 0.6 % within the linear regime. 
Cytocompatibility studies using MTT assays. The cytotoxicity of C16EELNRYY and 
ELELNRYY was examined. In vitro cell culture was carried out using the HCT-116 human 
colorectal tumour cell line. Cells were cultured in McCoys 5A modified medium with 10% 
fetal bovine serum (FBS), and 1% antibiotic-antimycotic (Thermoscientific, 100×). Cells 
were maintained in a humidified atmosphere of 5 % CO2 at 37 ° C. Cell viability effects 
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were examined using the MTT 3-(4,5- dimethylthiazol-2-yl)-2,5- diphenyltetrazolium 
bromide) assay. The peptide was dissolved in complete medium. Cells were seeded into 
a 96-well plate at a seeding density of 4 × 104 cells/mL, and allowed to adhere for 24 h 
in 100 μL complete medium. After 24 h, a total volume of 100 μL of either complete 
medium and/or peptide solution was added, to give final peptide concentrations of 0.08, 
0.04, 0.02, 0.008, 0.00481, 0.002, 0.001, 0.0008 or 0.0004 wt% peptide. Negative 
controls of peptide in complete medium with no cells were included. After 67 h of 
incubation, 20 μL of MTT (0.5 wt% in PBS) was added to each well plate and allowed to 
incubate for 5 h (total of 72 h incubation). After this, the solutions were removed from 
the wells and replaced with 100 μL DMSO per well in order to dissolve the formazan 
crystals. Plates were incubated for 30 min, and then analyzed using a UV microplate 
reader (λ = 570 nm). Results are reported [(treated cells − negative control)/(untreated 
cells)] × 100.38−40. 
 
 
 
 
 
 
 
 
